https://trial.medpath.com/news/lykos-could-see-five-year-delay-in-possible-fda-approval-of-mdma-inside-health-policy 2024-09-17T02:17:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lykos-could-see-five-year-delay-in-possible-fda-approval-of-mdma-inside-health-policy 2024-09-17T02:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-draft-guidance-on-conducting-multiregional-clinical-trials-in-oncology 2024-09-17T02:07:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-on-conducting-multiregional-clinical-trials-in-oncology 2024-09-17T02:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-17T02:07:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-17T02:07:19+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-fecal-microbiota-transplantation-vs-placebo-in-patients-receiving-urotoday 2024-09-17T01:35:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-fecal-microbiota-transplantation-vs-placebo-in-patients-receiving-urotoday 2024-09-17T01:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-perioperative-imfinzi-significantly-extends-survival-in-type-of-bladder-cancer 2024-09-17T01:10:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-perioperative-imfinzi-significantly-extends-survival-in-type-of-bladder-cancer 2024-09-17T01:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaust-seeks-european-orphan-drug-designation-for-mnd-als-drug-monepantel 2024-09-17T00:43:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmaust-seeks-european-orphan-drug-designation-for-mnd-als-drug-monepantel 2024-09-17T00:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/drug-safety-experts-call-for-enhanced-diagnostic-accuracy-in-clinical-trials-to-protect-patient-safety 2024-09-17T00:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-safety-experts-call-for-enhanced-diagnostic-accuracy-in-clinical-trials-to-protect-patient-safety 2024-09-17T00:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/ipf-drug-meets-primary-end-point-managed-healthcare-executive 2024-09-17T00:24:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipf-drug-meets-primary-end-point-managed-healthcare-executive 2024-09-17T00:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/launch-of-yselty-r-generic-name-linzagolix-for-uterine-fibroid-treatment-in-europe 2024-09-17T00:21:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/launch-of-yselty-r-generic-name-linzagolix-for-uterine-fibroid-treatment-in-europe 2024-09-17T00:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/5-year-analysis-of-phase-iii-himalaya-confirms-survival-benefit-of-stride-in 2024-09-16T22:22:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-year-analysis-of-phase-iii-himalaya-confirms-survival-benefit-of-stride-in 2024-09-16T22:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-manufacturing-line-for-rsv-therapy-becker-s-hospital-review 2024-09-16T21:58:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-manufacturing-line-for-rsv-therapy-becker-s-hospital-review 2024-09-16T21:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/elderly-monkeys-aged-more-slowly-when-given-a-cheap-diabetes-drug-used-by-millions 2024-09-16T21:42:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elderly-monkeys-aged-more-slowly-when-given-a-cheap-diabetes-drug-used-by-millions 2024-09-16T21:42:16+00:00 weekly 0.7 https://trial.medpath.com/news/darolutamide-in-combination-with-androgen-deprivation-therapy-in-patients-with-urotoday 2024-09-16T21:25:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/darolutamide-in-combination-with-androgen-deprivation-therapy-in-patients-with-urotoday 2024-09-16T21:25:51+00:00 weekly 0.7 https://trial.medpath.com/news/qu-scientists-in-precision-medicine-breakthrough-gulf-times 2024-09-16T21:08:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qu-scientists-in-precision-medicine-breakthrough-gulf-times 2024-09-16T21:08:54+00:00 weekly 0.7 https://trial.medpath.com/news/pei-yu-chen-phd-aims-to-create-a-safer-and-more-effective-way-to-deliver-drugs 2024-09-16T21:07:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pei-yu-chen-phd-aims-to-create-a-safer-and-more-effective-way-to-deliver-drugs 2024-09-16T21:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-trial-highlights-potential-of-inavolisib-for-pik3ca-mutated-cancers 2024-09-16T21:03:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-trial-highlights-potential-of-inavolisib-for-pik3ca-mutated-cancers 2024-09-16T21:03:01+00:00 weekly 0.7 https://trial.medpath.com/news/poor-outcomes-after-tpoxx-mpox-treatment-mainly-seen-in-those-with-weak-immunity 2024-09-16T20:47:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poor-outcomes-after-tpoxx-mpox-treatment-mainly-seen-in-those-with-weak-immunity 2024-09-16T20:47:54+00:00 weekly 0.7 https://trial.medpath.com/news/biotronik-catheter-gets-fda-approval-daic 2024-09-16T20:44:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotronik-catheter-gets-fda-approval-daic 2024-09-16T20:44:43+00:00 weekly 0.7 https://trial.medpath.com/news/duke-physician-highlights-positive-ovarian-cancer-clinical-trial-results 2024-09-16T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/duke-physician-highlights-positive-ovarian-cancer-clinical-trial-results 2024-09-16T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/amg-193-shows-preliminary-clinical-activity-in-mtap-deleted-solid-tumors-onclive 2024-09-16T20:28:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amg-193-shows-preliminary-clinical-activity-in-mtap-deleted-solid-tumors-onclive 2024-09-16T20:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/brain-metastases-of-her2-positive-breast-cancer-patients-effectively-treated-with-antibody 2024-09-16T20:23:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brain-metastases-of-her2-positive-breast-cancer-patients-effectively-treated-with-antibody 2024-09-16T20:23:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-apple-watch-sleep-apnea-detection-notification-appleinsider 2024-09-16T20:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-apple-watch-sleep-apnea-detection-notification-appleinsider 2024-09-16T20:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-mm-ii-fast-track-designation-for-treatment-of-osteoarthritis-knee-pain 2024-09-16T20:09:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-mm-ii-fast-track-designation-for-treatment-of-osteoarthritis-knee-pain 2024-09-16T20:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-drafts-guidance-on-multiregional-clinical-trials-in-oncology-raps 2024-09-16T19:49:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-drafts-guidance-on-multiregional-clinical-trials-in-oncology-raps 2024-09-16T19:49:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lebrikizumab-for-treatment-of-atopic-dermatitis-pharmacy-times 2024-09-16T19:48:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lebrikizumab-for-treatment-of-atopic-dermatitis-pharmacy-times 2024-09-16T19:48:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-insights-epcoritamab-in-relapsed-refractory-follicular-lymphoma-onclive 2024-09-16T19:44:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-insights-epcoritamab-in-relapsed-refractory-follicular-lymphoma-onclive 2024-09-16T19:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-announce-clinical-trial-results-for-hard-to-treat-breast-and-bladder-cancers 2024-09-16T19:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-announce-clinical-trial-results-for-hard-to-treat-breast-and-bladder-cancers 2024-09-16T19:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-sny-win-fda-approval-for-a-broader-dupixent-label-yahoo-finance 2024-09-16T19:08:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-sny-win-fda-approval-for-a-broader-dupixent-label-yahoo-finance 2024-09-16T19:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/newly-initiated-phase-2-breakthrough-trial-to-test-5-ht2c-receptor-agonist-bmb-101 2024-09-16T19:08:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newly-initiated-phase-2-breakthrough-trial-to-test-5-ht2c-receptor-agonist-bmb-101 2024-09-16T19:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/keynote-522-findings-continue-to-shape-the-future-of-tnbc-care-targeted-oncology 2024-09-16T19:05:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keynote-522-findings-continue-to-shape-the-future-of-tnbc-care-targeted-oncology 2024-09-16T19:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-improves-outcomes-in-high-risk-bladder-cancer-nci 2024-09-16T18:44:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-improves-outcomes-in-high-risk-bladder-cancer-nci 2024-09-16T18:44:32+00:00 weekly 0.7 https://trial.medpath.com/news/techcrunch-minute-fda-approval-sets-the-stage-for-apple-s-airpod-hearing-aids 2024-09-16T18:38:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/techcrunch-minute-fda-approval-sets-the-stage-for-apple-s-airpod-hearing-aids 2024-09-16T18:38:27+00:00 weekly 0.7 https://trial.medpath.com/news/apple-gets-fda-approval-for-smartwatch-sleep-apnea-detection-feature-investopedia 2024-09-16T18:29:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-gets-fda-approval-for-smartwatch-sleep-apnea-detection-feature-investopedia 2024-09-16T18:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/tremelimumab-plus-durvalumab-turns-heads-with-updated-five-year-data-in-uhcc 2024-09-16T18:27:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tremelimumab-plus-durvalumab-turns-heads-with-updated-five-year-data-in-uhcc 2024-09-16T18:27:31+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-and-novel-targeted-drug-appear-beneficial-in-women-with-early-stage 2024-09-16T18:27:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-and-novel-targeted-drug-appear-beneficial-in-women-with-early-stage 2024-09-16T18:27:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-apple-s-sleep-apnea-detection-feature-for-use-here-s-how-it-works-cnbc 2024-09-16T18:12:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-apple-s-sleep-apnea-detection-feature-for-use-here-s-how-it-works-cnbc 2024-09-16T18:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ebglyss-for-moderate-to-severe-atopic-dermatitis-pharmaceutical-executive 2024-09-16T18:09:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ebglyss-for-moderate-to-severe-atopic-dermatitis-pharmaceutical-executive 2024-09-16T18:09:15+00:00 weekly 0.7 https://trial.medpath.com/news/new-eli-lilly-eczema-drug-brings-competition-and-dosing-edge-versus-sanofi-leo-pharma-meds 2024-09-16T17:56:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-eli-lilly-eczema-drug-brings-competition-and-dosing-edge-versus-sanofi-leo-pharma-meds 2024-09-16T17:56:47+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss-benzinga 2024-09-16T17:52:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss-benzinga 2024-09-16T17:52:46+00:00 weekly 0.7 https://trial.medpath.com/news/recon-astrazeneca-releases-positive-results-on-imfinzi-for-bladder-cancer-raps 2024-09-16T17:26:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recon-astrazeneca-releases-positive-results-on-imfinzi-for-bladder-cancer-raps 2024-09-16T17:26:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-biotronik-lead-catheter-for-left-bundle-branch-area-pacing 2024-09-16T17:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-biotronik-lead-catheter-for-left-bundle-branch-area-pacing 2024-09-16T17:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/medical-marijuana-users-see-short-term-gains-in-he-newswise 2024-09-16T17:06:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medical-marijuana-users-see-short-term-gains-in-he-newswise 2024-09-16T17:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/evaxion-reports-convincing-one-year-data-from-phase-2-trial-on-ai-designed-personalized 2024-09-16T17:02:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaxion-reports-convincing-one-year-data-from-phase-2-trial-on-ai-designed-personalized 2024-09-16T17:02:55+00:00 weekly 0.7 https://trial.medpath.com/news/rewriting-the-health-care-script-in-africa-c-en-american-chemical-society 2024-09-16T16:48:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rewriting-the-health-care-script-in-africa-c-en-american-chemical-society 2024-09-16T16:48:05+00:00 weekly 0.7 https://trial.medpath.com/news/dr-nicolas-girard-on-luminosity-teliso-v-improves-pros-in-nsclc 2024-09-16T16:47:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-nicolas-girard-on-luminosity-teliso-v-improves-pros-in-nsclc 2024-09-16T16:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-gains-fda-approval-for-expanded-use-in-adolescents-with-crswnp 2024-09-16T16:46:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-gains-fda-approval-for-expanded-use-in-adolescents-with-crswnp 2024-09-16T16:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/leigh-s-lost-and-found-local-vet-office-takes-part-in-clinical-trial-to-extend-dogs-lives-ky3 2024-09-16T16:42:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leigh-s-lost-and-found-local-vet-office-takes-part-in-clinical-trial-to-extend-dogs-lives-ky3 2024-09-16T16:42:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-catheter-system-for-left-bundle-branch-area-pacing-healio 2024-09-16T16:35:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-catheter-system-for-left-bundle-branch-area-pacing-healio 2024-09-16T16:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-signs-agreements-for-first-in-human-clinical-trials-of-four-new-molecules 2024-09-16T16:35:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icmr-signs-agreements-for-first-in-human-clinical-trials-of-four-new-molecules 2024-09-16T16:35:08+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T16:33:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T16:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-submits-carotid-stent-for-fda-premarket-approval-massdevice 2024-09-16T16:28:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspiremd-submits-carotid-stent-for-fda-premarket-approval-massdevice 2024-09-16T16:28:03+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-s-sleep-apnea-detection-feature-gets-fda-approval-here-s-how-it-will-work 2024-09-16T16:27:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-s-sleep-apnea-detection-feature-gets-fda-approval-here-s-how-it-will-work 2024-09-16T16:27:30+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-moves-novo-nordisk-s-liraglutide-scores-in-phase-iii-paediatric-trial 2024-09-16T16:24:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pipeline-moves-novo-nordisk-s-liraglutide-scores-in-phase-iii-paediatric-trial 2024-09-16T16:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-sleep-apnea-detection-gets-fda-approval-healthleaders-media 2024-09-16T16:13:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-sleep-apnea-detection-gets-fda-approval-healthleaders-media 2024-09-16T16:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-hold-on-zentalis-cancer-drug-trials-investing-com 2024-09-16T16:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-hold-on-zentalis-cancer-drug-trials-investing-com 2024-09-16T16:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ocrevus-zunovo-for-relapsing-primary-progressive-multiple-sclerosis 2024-09-16T16:08:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ocrevus-zunovo-for-relapsing-primary-progressive-multiple-sclerosis 2024-09-16T16:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-seeks-approval-for-lung-fibrosis-drug-following-phase-iii-win-yahoo 2024-09-16T16:08:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-seeks-approval-for-lung-fibrosis-drug-following-phase-iii-win-yahoo 2024-09-16T16:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-of-its-kind-cardiac-stent-for-babies-newswise 2024-09-16T16:08:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-of-its-kind-cardiac-stent-for-babies-newswise 2024-09-16T16:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/50-years-of-the-cure-celebrating-pioneering-iu-research-and-the-cure-for-testicular-cancer 2024-09-16T16:07:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/50-years-of-the-cure-celebrating-pioneering-iu-research-and-the-cure-for-testicular-cancer 2024-09-16T16:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/splash-177lu-pnt2002-achieves-phase-3-outcomes-for-mcrpc-urology-times 2024-09-16T16:04:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/splash-177lu-pnt2002-achieves-phase-3-outcomes-for-mcrpc-urology-times 2024-09-16T16:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-after-surgery-helps-people-with-high-risk-bladder-cancer-live-cancer-free-longer 2024-09-16T15:56:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-after-surgery-helps-people-with-high-risk-bladder-cancer-live-cancer-free-longer 2024-09-16T15:56:31+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-early-stage-triple-negative-breast-cancer 2024-09-16T15:46:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-early-stage-triple-negative-breast-cancer 2024-09-16T15:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/ten-year-data-from-checkmate-067-trial-shows-long-term-survival-benefits-of-opdivo 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ten-year-data-from-checkmate-067-trial-shows-long-term-survival-benefits-of-opdivo 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-plus-imjudo-shows-significant-five-year-survival-improvement-in-unresectable-liver-cancer 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-plus-imjudo-shows-significant-five-year-survival-improvement-in-unresectable-liver-cancer 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/chemo-free-triplet-yields-68-response-rate-in-richter-transformation-medpage-today 2024-09-16T15:45:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemo-free-triplet-yields-68-response-rate-in-richter-transformation-medpage-today 2024-09-16T15:45:37+00:00 weekly 0.7 https://trial.medpath.com/news/new-eczema-drug-from-eli-lilly-receives-fda-approval-for-children-and-adults-usa-today 2024-09-16T15:42:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-eczema-drug-from-eli-lilly-receives-fda-approval-for-children-and-adults-usa-today 2024-09-16T15:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/alliance-presents-final-results-from-phase-ii-eurekalert 2024-09-16T15:42:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alliance-presents-final-results-from-phase-ii-eurekalert 2024-09-16T15:42:23+00:00 weekly 0.7 https://trial.medpath.com/news/guru-sonpavde-md-on-phase-3-ambassador-trial-data-in-urothelial-carcinoma 2024-09-16T15:40:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/guru-sonpavde-md-on-phase-3-ambassador-trial-data-in-urothelial-carcinoma 2024-09-16T15:40:56+00:00 weekly 0.7 https://trial.medpath.com/news/pooled-trust-i-and-trust-ii-data-affirm-taletrectinib-benefits-for-advanced-ros1-nsclc 2024-09-16T15:40:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pooled-trust-i-and-trust-ii-data-affirm-taletrectinib-benefits-for-advanced-ros1-nsclc 2024-09-16T15:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-partial-clinical-hold-on-trials-evaluating-azenosertib-in-advanced-solid-tumors 2024-09-16T15:40:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-partial-clinical-hold-on-trials-evaluating-azenosertib-in-advanced-solid-tumors 2024-09-16T15:40:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-p-bcma-allo1-rmat-designation-in-r-r-multiple-myeloma 2024-09-16T15:35:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-p-bcma-allo1-rmat-designation-in-r-r-multiple-myeloma 2024-09-16T15:35:05+00:00 weekly 0.7 https://trial.medpath.com/news/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:21:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-targets-expanded-use-approval-for-prostate-cancer-drug-reveals-encouraging 2024-09-16T15:21:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-targets-expanded-use-approval-for-prostate-cancer-drug-reveals-encouraging 2024-09-16T15:21:07+00:00 weekly 0.7 https://trial.medpath.com/news/biotronik-earns-expanded-fda-nod-for-pacing-lead-delivery-catheter-system-massdevice 2024-09-16T15:19:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotronik-earns-expanded-fda-nod-for-pacing-lead-delivery-catheter-system-massdevice 2024-09-16T15:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/addressing-disparities-in-food-allergen-immunotherapy-trials-jama-network 2024-09-16T15:18:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addressing-disparities-in-food-allergen-immunotherapy-trials-jama-network 2024-09-16T15:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/first-group-of-healthy-volunteers-dosed-in-qrl-101-mad-study-als-news-today 2024-09-16T15:14:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-group-of-healthy-volunteers-dosed-in-qrl-101-mad-study-als-news-today 2024-09-16T15:14:15+00:00 weekly 0.7 https://trial.medpath.com/news/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:13:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:13:03+00:00 weekly 0.7 https://trial.medpath.com/news/some-men-with-prostate-cancer-can-benefit-from-immunotherapy 2024-09-16T15:12:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/some-men-with-prostate-cancer-can-benefit-from-immunotherapy 2024-09-16T15:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-sleep-apnea-detection-gets-fda-clearance-the-verge 2024-09-16T15:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-sleep-apnea-detection-gets-fda-clearance-the-verge 2024-09-16T15:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-review-dupilumab-lebrikizumab-fda-approved-plus-much-more-contemporary-pediatrics 2024-09-16T15:11:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekly-review-dupilumab-lebrikizumab-fda-approved-plus-much-more-contemporary-pediatrics 2024-09-16T15:11:59+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-could-curb-progression-of-diabetes-linked-liver-disease 2024-09-16T15:09:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-could-curb-progression-of-diabetes-linked-liver-disease 2024-09-16T15:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/three-apple-watches-get-fda-approval-for-sleep-apnea-detection-from-today-9to5mac 2024-09-16T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-apple-watches-get-fda-approval-for-sleep-apnea-detection-from-today-9to5mac 2024-09-16T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-durvalumab-with-neoadjuvant-chemo-boosts-survival-in-cisplatin-eligible-mibc 2024-09-16T15:08:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-durvalumab-with-neoadjuvant-chemo-boosts-survival-in-cisplatin-eligible-mibc 2024-09-16T15:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lebrikizumab-for-patients-aged-12-and-older-with-moderate-to-severe 2024-09-16T15:05:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lebrikizumab-for-patients-aged-12-and-older-with-moderate-to-severe 2024-09-16T15:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-shelves-cabometyx-combo-in-prostate-cancer-after-phase-iii-miss 2024-09-16T15:00:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipsen-shelves-cabometyx-combo-in-prostate-cancer-after-phase-iii-miss 2024-09-16T15:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/apac-roundup-cdsco-releases-draft-guidelines-on-good-clinical-practices-for-consultation-raps 2024-09-16T14:59:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apac-roundup-cdsco-releases-draft-guidelines-on-good-clinical-practices-for-consultation-raps 2024-09-16T14:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/leap-012-pembrolizumab-plus-lenvatinib-added-to-tace-improved-progression-free 2024-09-16T14:51:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leap-012-pembrolizumab-plus-lenvatinib-added-to-tace-improved-progression-free 2024-09-16T14:51:36+00:00 weekly 0.7 https://trial.medpath.com/news/positive-trial-demonstrates-safe-breastfeeding-during-endocrine-therapy-break-for-hr-breast-cancer-patients 2024-09-16T14:48:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-trial-demonstrates-safe-breastfeeding-during-endocrine-therapy-break-for-hr-breast-cancer-patients 2024-09-16T14:48:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-tecentriq-hybreza-cancer-therapy-advisor 2024-09-16T14:47:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-tecentriq-hybreza-cancer-therapy-advisor 2024-09-16T14:47:48+00:00 weekly 0.7 https://trial.medpath.com/news/ocrevus-zunovo-now-approved-in-us-to-treat-relapsing-ms-ppms 2024-09-16T14:44:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocrevus-zunovo-now-approved-in-us-to-treat-relapsing-ms-ppms 2024-09-16T14:44:02+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease 2024-09-16T14:43:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease 2024-09-16T14:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/new-trial-to-test-potential-treatment-for-chronic-kidney-disease 2024-09-16T14:43:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-trial-to-test-potential-treatment-for-chronic-kidney-disease 2024-09-16T14:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T14:42:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T14:42:48+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-breast-cancer-drug-found-to-cut-disease-recurrence-investopedia 2024-09-16T14:33:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-breast-cancer-drug-found-to-cut-disease-recurrence-investopedia 2024-09-16T14:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/risk-for-second-primary-cancer-may-be-no-higher-with-car-t-cell-versus-standard-of-care 2024-09-16T14:32:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/risk-for-second-primary-cancer-may-be-no-higher-with-car-t-cell-versus-standard-of-care 2024-09-16T14:32:07+00:00 weekly 0.7 https://trial.medpath.com/news/sec-form-424b5-filed-by-inmune-bio-inc-quantisnow 2024-09-16T14:26:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sec-form-424b5-filed-by-inmune-bio-inc-quantisnow 2024-09-16T14:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/trishula-therapeutics-presents-positive-results-from-phase-1-trial-of-ttx-030-in-first-line-metastatic-pancreatic-cancer-patients 2024-09-16T14:09:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trishula-therapeutics-presents-positive-results-from-phase-1-trial-of-ttx-030-in-first-line-metastatic-pancreatic-cancer-patients 2024-09-16T14:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-and-adjuvant-pembrolizumab-extends-survival-in-early-stage-tnbc 2024-09-16T14:03:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-and-adjuvant-pembrolizumab-extends-survival-in-early-stage-tnbc 2024-09-16T14:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-drug-treating-fatal-weight-loss-in-cancer-patients-found-effective-investopedia 2024-09-16T13:57:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-drug-treating-fatal-weight-loss-in-cancer-patients-found-effective-investopedia 2024-09-16T13:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-clinical-trials-arena 2024-09-16T13:56:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-clinical-trials-arena 2024-09-16T13:56:08+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-sleep-apnea-detection-gets-fda-approval-techcrunch 2024-09-16T13:48:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-sleep-apnea-detection-gets-fda-approval-techcrunch 2024-09-16T13:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-j-j-cues-up-phase-3-for-rybrevant-in-colorectal-cancer-pharmaphorum 2024-09-16T13:36:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-j-j-cues-up-phase-3-for-rybrevant-in-colorectal-cancer-pharmaphorum 2024-09-16T13:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-s-sleep-apnea-notification-feature-granted-fda-approval-tom-s-guide 2024-09-16T13:34:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-s-sleep-apnea-notification-feature-granted-fda-approval-tom-s-guide 2024-09-16T13:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-yahoo-finance 2024-09-16T13:31:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-yahoo-finance 2024-09-16T13:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/alliance-unveils-phase-iii-cabozantinib-trial-results-at-esmo-mirage-news 2024-09-16T13:30:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alliance-unveils-phase-iii-cabozantinib-trial-results-at-esmo-mirage-news 2024-09-16T13:30:47+00:00 weekly 0.7 https://trial.medpath.com/news/vera-therapeutics-to-host-in-person-r-d-day-in-new-york-to-discuss-potential-indication 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vera-therapeutics-to-host-in-person-r-d-day-in-new-york-to-discuss-potential-indication 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/biovie-secures-all-scientific-approvals-needed-to-receive-additional-12-6-million-of-grant 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biovie-secures-all-scientific-approvals-needed-to-receive-additional-12-6-million-of-grant 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T13:29:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T13:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-data-from-versatile-002-phase-2-study-in-hnscc 2024-09-16T13:26:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-announces-updated-data-from-versatile-002-phase-2-study-in-hnscc 2024-09-16T13:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/cvkd-new-blood-thinner-ready-for-phase-3-initiating-coverage-of-cadrenal-therapeutics-inc 2024-09-16T13:24:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cvkd-new-blood-thinner-ready-for-phase-3-initiating-coverage-of-cadrenal-therapeutics-inc 2024-09-16T13:24:34+00:00 weekly 0.7 https://trial.medpath.com/news/nimmune-biopharma-to-participate-in-ubs-virtual-biotechnology-private-company-symposium 2024-09-16T13:19:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nimmune-biopharma-to-participate-in-ubs-virtual-biotechnology-private-company-symposium 2024-09-16T13:19:09+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-s-sleep-apnea-detection-feature-receives-fda-approval-macrumors 2024-09-16T13:12:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-s-sleep-apnea-detection-feature-receives-fda-approval-macrumors 2024-09-16T13:12:39+00:00 weekly 0.7 https://trial.medpath.com/news/vivtex-enters-new-research-agreement-with-equillium-to-develop-gi-targeted-formulations 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivtex-enters-new-research-agreement-with-equillium-to-develop-gi-targeted-formulations 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/second-generation-of-i-spy-2-trial-design-is-driving-the-precise-in-precision-medicine 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/second-generation-of-i-spy-2-trial-design-is-driving-the-precise-in-precision-medicine 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease-new 2024-09-16T13:04:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease-new 2024-09-16T13:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/shuttle-pharma-expands-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-stock-titan 2024-09-16T13:01:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shuttle-pharma-expands-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-stock-titan 2024-09-16T13:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:01:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-tradingview 2024-09-16T12:53:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-tradingview 2024-09-16T12:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in-ipsen 2024-09-16T12:52:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in-ipsen 2024-09-16T12:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/don-t-count-out-cipher-pharma-research-capital-says-cantech-letter 2024-09-16T12:52:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/don-t-count-out-cipher-pharma-research-capital-says-cantech-letter 2024-09-16T12:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-iteos-score-phase-ii-win-for-jemperli-tigit-combo-in-nsclc-biospace 2024-09-16T12:52:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-iteos-score-phase-ii-win-for-jemperli-tigit-combo-in-nsclc-biospace 2024-09-16T12:52:21+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-globenewswire 2024-09-16T12:50:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-results-from-cabinet-phase-iii-trial-reinforce-globenewswire 2024-09-16T12:50:51+00:00 weekly 0.7 https://trial.medpath.com/news/september-16-2024-researchers-examine-feasibility-of-enhanced-tsos-intervention-for 2024-09-16T12:50:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-16-2024-researchers-examine-feasibility-of-enhanced-tsos-intervention-for 2024-09-16T12:50:17+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in 2024-09-16T12:49:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in 2024-09-16T12:49:05+00:00 weekly 0.7 https://trial.medpath.com/news/clene-granted-in-person-meeting-with-fda-senior-leadership-to-discuss-cnm-au8 2024-09-16T12:42:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clene-granted-in-person-meeting-with-fda-senior-leadership-to-discuss-cnm-au8 2024-09-16T12:42:23+00:00 weekly 0.7 https://trial.medpath.com/news/china-grants-btd-to-blenrep-with-bordex-for-multiple-myeloma 2024-09-16T12:41:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-grants-btd-to-blenrep-with-bordex-for-multiple-myeloma 2024-09-16T12:41:07+00:00 weekly 0.7 https://trial.medpath.com/news/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T12:39:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T12:39:11+00:00 weekly 0.7 https://trial.medpath.com/news/mizuho-maintains-neutral-rating-on-apellis-stock-with-steady-price-target-investing-com 2024-09-16T12:37:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mizuho-maintains-neutral-rating-on-apellis-stock-with-steady-price-target-investing-com 2024-09-16T12:37:27+00:00 weekly 0.7 https://trial.medpath.com/news/data-from-a-phase-1-trial-of-highfield-biopharmaceuticals-hf1k16-show-the-new-immuno 2024-09-16T12:36:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-from-a-phase-1-trial-of-highfield-biopharmaceuticals-hf1k16-show-the-new-immuno 2024-09-16T12:36:58+00:00 weekly 0.7 https://trial.medpath.com/news/bio-path-holdings-announces-publication-in-biomedicines-biospace 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bio-path-holdings-announces-publication-in-biomedicines-biospace 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-to-present-positive-interim-data-from-cohort-1-patients-with-ftd-grn-in-uplift 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/passage-bio-to-present-positive-interim-data-from-cohort-1-patients-with-ftd-grn-in-uplift 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/gigapath-ai-model-shows-superior-accuracy-in-predicting-cancer-mutations-and-tumor-burden 2024-09-16T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gigapath-ai-model-shows-superior-accuracy-in-predicting-cancer-mutations-and-tumor-burden 2024-09-16T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-aims-for-single-dose-malaria-cure-with-a-novel-moa-long-acting-aryl-sf5-compound 2024-09-16T12:25:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-aims-for-single-dose-malaria-cure-with-a-novel-moa-long-acting-aryl-sf5-compound 2024-09-16T12:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-injectable-pd-l1-inhibitor-granted-fda-approval-for-multiple-cancer-types-pmlive 2024-09-16T12:21:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-injectable-pd-l1-inhibitor-granted-fda-approval-for-multiple-cancer-types-pmlive 2024-09-16T12:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-highlights-complexities-of-central-centrifugal-cicatricial-alopecia-in-diverse-populations 2024-09-16T12:21:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-research-highlights-complexities-of-central-centrifugal-cicatricial-alopecia-in-diverse-populations 2024-09-16T12:21:09+00:00 weekly 0.7 https://trial.medpath.com/news/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-stock-titan 2024-09-16T12:20:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-stock-titan 2024-09-16T12:20:17+00:00 weekly 0.7 https://trial.medpath.com/news/infex-therapeutics-first-ncfb-patient-dosed-in-resp-x-phase-iia-study-research-tree 2024-09-16T12:19:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/infex-therapeutics-first-ncfb-patient-dosed-in-resp-x-phase-iia-study-research-tree 2024-09-16T12:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-corporation-announces-updated-results-from-versatile-002-phase 2024-09-16T12:15:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotechnology-corporation-announces-updated-results-from-versatile-002-phase 2024-09-16T12:15:57+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-aranote-trial-shows-nubeqa-r-darolutamide-significantly-reduced-risk-of 2024-09-16T12:10:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-aranote-trial-shows-nubeqa-r-darolutamide-significantly-reduced-risk-of 2024-09-16T12:10:19+00:00 weekly 0.7 https://trial.medpath.com/news/aethlon-medical-announces-activation-of-royal-adelaide-hospital-to-begin-patient-markets-data 2024-09-16T12:09:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aethlon-medical-announces-activation-of-royal-adelaide-hospital-to-begin-patient-markets-data 2024-09-16T12:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-placera 2024-09-16T12:05:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-placera 2024-09-16T12:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-announces-submission-of-premarket-approval-application-to-fda-seeking-u-s 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspiremd-announces-submission-of-premarket-approval-application-to-fda-seeking-u-s 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-markets-insider 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-markets-insider 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-niagara-backs-imfinzi-in-bladder-cancer-but-will-fda-pharmaphorum 2024-09-16T11:58:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-niagara-backs-imfinzi-in-bladder-cancer-but-will-fda-pharmaphorum 2024-09-16T11:58:24+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-seeks-fda-approval-for-carotid-stent-system-investing-com 2024-09-16T11:49:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspiremd-seeks-fda-approval-for-carotid-stent-system-investing-com 2024-09-16T11:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/evaxion-reports-promising-phase-2-trial-results-for-cancer-vaccine-investing-com 2024-09-16T11:49:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaxion-reports-promising-phase-2-trial-results-for-cancer-vaccine-investing-com 2024-09-16T11:49:49+00:00 weekly 0.7 https://trial.medpath.com/news/medexus-provides-update-on-treosulfan-nda-review-process-and-extended-pdufa-goal-date 2024-09-16T11:48:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medexus-provides-update-on-treosulfan-nda-review-process-and-extended-pdufa-goal-date 2024-09-16T11:48:34+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-announces-fda-approval-for-ebglyss-in-moderate-to-severe-atopic-dermatitis 2024-09-16T11:43:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-announces-fda-approval-for-ebglyss-in-moderate-to-severe-atopic-dermatitis 2024-09-16T11:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-marketscreener 2024-09-16T11:37:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-marketscreener 2024-09-16T11:37:45+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-upgraded-by-jp-morgan-with-a-new-price-target-quantisnow 2024-09-16T11:36:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biontech-upgraded-by-jp-morgan-with-a-new-price-target-quantisnow 2024-09-16T11:36:47+00:00 weekly 0.7 https://trial.medpath.com/news/zentalis-pharmaceuticals-announces-fda-has-lifted-partial-clinical-hold-on-azenosertib-studies 2024-09-16T11:32:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zentalis-pharmaceuticals-announces-fda-has-lifted-partial-clinical-hold-on-azenosertib-studies 2024-09-16T11:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/japan-s-mhlw-approves-csl-arcturus-updated-sa-mrna-covid-19-vaccine-for 2024-09-16T11:29:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/japan-s-mhlw-approves-csl-arcturus-updated-sa-mrna-covid-19-vaccine-for 2024-09-16T11:29:39+00:00 weekly 0.7 https://trial.medpath.com/news/phytohealth-corporation-announced-a-new-clinical-study-results-published-at-2024-esmo-congress 2024-09-16T11:23:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phytohealth-corporation-announced-a-new-clinical-study-results-published-at-2024-esmo-congress 2024-09-16T11:23:12+00:00 weekly 0.7 https://trial.medpath.com/news/acrivon-therapeutics-promising-trial-results-and-fda-clearance-tipranks-com 2024-09-16T11:20:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acrivon-therapeutics-promising-trial-results-and-fda-clearance-tipranks-com 2024-09-16T11:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-stock-titan 2024-09-16T11:19:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-stock-titan 2024-09-16T11:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-16T11:19:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-16T11:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-announces-updates-data-from-versatile-002-trial-tipranks-com 2024-09-16T11:15:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotechnology-announces-updates-data-from-versatile-002-trial-tipranks-com 2024-09-16T11:15:23+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-to-present-positive-interim-data-from-cohort-1-globenewswire 2024-09-16T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/passage-bio-to-present-positive-interim-data-from-cohort-1-globenewswire 2024-09-16T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-is-a-game-changer-in-heart-valve-technology-health-tech-world 2024-09-16T11:07:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-is-a-game-changer-in-heart-valve-technology-health-tech-world 2024-09-16T11:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-announces-updated-analysis-from-phase-iii-natalee-trial-tipranks-com 2024-09-16T11:05:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-announces-updated-analysis-from-phase-iii-natalee-trial-tipranks-com 2024-09-16T11:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-r-durvalumab-plus-imjudo-r-tremelimumab-actl-demonstrated-unprecedented 2024-09-16T11:03:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-r-durvalumab-plus-imjudo-r-tremelimumab-actl-demonstrated-unprecedented 2024-09-16T11:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/strides-pharma-gets-fda-nod-for-generic-antidepressant-fluoxetine-60-mg-tablet 2024-09-16T11:02:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strides-pharma-gets-fda-nod-for-generic-antidepressant-fluoxetine-60-mg-tablet 2024-09-16T11:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-results-from-versatile-002-globenewswire 2024-09-16T11:02:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-announces-updated-results-from-versatile-002-globenewswire 2024-09-16T11:02:07+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T11:01:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T11:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-roche-s-ocrevus-zunovo-with-halozyme-enhanze-delivery-tech 2024-09-16T10:55:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-roche-s-ocrevus-zunovo-with-halozyme-enhanze-delivery-tech 2024-09-16T10:55:21+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T10:49:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T10:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/epitomee-surges-200-in-two-days-on-fda-approval-for-weight-loss-pill-ctech 2024-09-16T10:49:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epitomee-surges-200-in-two-days-on-fda-approval-for-weight-loss-pill-ctech 2024-09-16T10:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/antennova-releases-latest-data-of-cd73-inhibitor-atn-037-including-a-dcr-of-89-5-in-a 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antennova-releases-latest-data-of-cd73-inhibitor-atn-037-including-a-dcr-of-89-5-in-a 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/promising-anti-tumor-activity-and-safety-of-ivonescimab-in-combination-therapies-in-crc 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-anti-tumor-activity-and-safety-of-ivonescimab-in-combination-therapies-in-crc 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-regeneron-s-melanoma-combo-therapy-benefit-continues-beyond-two-years 2024-09-16T10:31:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-regeneron-s-melanoma-combo-therapy-benefit-continues-beyond-two-years 2024-09-16T10:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/pd-1-checkpoint-inhibitor-shows-promise-for-anal-cancer 2024-09-16T10:29:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pd-1-checkpoint-inhibitor-shows-promise-for-anal-cancer 2024-09-16T10:29:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-boosts-weight-loss-pill-co-epitomee-globes-english-glvbs 2024-09-16T10:28:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-boosts-weight-loss-pill-co-epitomee-globes-english-glvbs 2024-09-16T10:28:36+00:00 weekly 0.7 https://trial.medpath.com/news/niagara-durvalumab-plus-chemo-improves-efs-and-os-in-cisplatin-eligible-mibc 2024-09-16T10:19:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/niagara-durvalumab-plus-chemo-improves-efs-and-os-in-cisplatin-eligible-mibc 2024-09-16T10:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-otc-hearing-aid-software-pharmaceutical-executive 2024-09-16T10:18:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-otc-hearing-aid-software-pharmaceutical-executive 2024-09-16T10:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/in-vivo-car-t-cells-move-into-clinical-trials-nature 2024-09-16T10:18:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-vivo-car-t-cells-move-into-clinical-trials-nature 2024-09-16T10:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/patientseek-identifies-a-genetic-signature-that-separates-a4b7-integrin-therapy-responder 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patientseek-identifies-a-genetic-signature-that-separates-a4b7-integrin-therapy-responder 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/certa-therapeutics-announces-international-non-proprietary-name-for-its-first-in-class 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/certa-therapeutics-announces-international-non-proprietary-name-for-its-first-in-class 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/this-drug-shows-promise-in-extending-bladder-cancer-patients-lives-newsbytes 2024-09-16T09:59:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-drug-shows-promise-in-extending-bladder-cancer-patients-lives-newsbytes 2024-09-16T09:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-receives-fda-approval-as-first-crswnp-treatment-pharmaceutical-technology 2024-09-16T09:58:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-receives-fda-approval-as-first-crswnp-treatment-pharmaceutical-technology 2024-09-16T09:58:59+00:00 weekly 0.7 https://trial.medpath.com/news/medsir-presents-new-studies-at-esmo-that-advance-treatment-of-patients-with-poor 2024-09-16T09:50:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medsir-presents-new-studies-at-esmo-that-advance-treatment-of-patients-with-poor 2024-09-16T09:50:05+00:00 weekly 0.7 https://trial.medpath.com/news/deep-behavioural-representation-learning-reveals-risk-profiles-for-malignant-ventricular-arrhythmias 2024-09-16T09:38:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deep-behavioural-representation-learning-reveals-risk-profiles-for-malignant-ventricular-arrhythmias 2024-09-16T09:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/elicio-therapeutics-announces-three-upcoming-presentations-focused-on-its-lymph-node 2024-09-16T09:37:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elicio-therapeutics-announces-three-upcoming-presentations-focused-on-its-lymph-node 2024-09-16T09:37:09+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-16T09:37:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-16T09:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/io-biotech-announces-positive-results-from-phase-2-trial-of-io102-io103-in-the-first-line 2024-09-16T09:37:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/io-biotech-announces-positive-results-from-phase-2-trial-of-io102-io103-in-the-first-line 2024-09-16T09:37:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute-biospace 2024-09-16T09:37:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute-biospace 2024-09-16T09:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours 2024-09-16T09:27:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours 2024-09-16T09:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/natera-announces-three-new-signatera-publications-includes-groundbreaking-overall 2024-09-16T09:26:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/natera-announces-three-new-signatera-publications-includes-groundbreaking-overall 2024-09-16T09:26:06+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-secures-fda-approval-for-ebglyss-to-treat-atopic-dermatitis 2024-09-16T09:22:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-secures-fda-approval-for-ebglyss-to-treat-atopic-dermatitis 2024-09-16T09:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours-yahoo-finance 2024-09-16T09:18:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours-yahoo-finance 2024-09-16T09:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-drugs-extend-survival-for-patients-with-advanced-melanomas 2024-09-16T09:09:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-drugs-extend-survival-for-patients-with-advanced-melanomas 2024-09-16T09:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-reducing-the-risk-of-recurrence 2024-09-16T08:49:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-reducing-the-risk-of-recurrence 2024-09-16T08:49:52+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:49:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:49:10+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:44:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-tremfya-r-for-ulcerative-colitis-treatment-promising-new-hope-for-patients 2024-09-16T08:32:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-tremfya-r-for-ulcerative-colitis-treatment-promising-new-hope-for-patients 2024-09-16T08:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-globenewswire 2024-09-16T08:19:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-globenewswire 2024-09-16T08:19:17+00:00 weekly 0.7 https://trial.medpath.com/news/gv20-therapeutics-reports-first-clinical-data-for-ai-designed-checkpoint-inhibitor-gv20-0251-in-advanced-solid-tumors 2024-09-16T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gv20-therapeutics-reports-first-clinical-data-for-ai-designed-checkpoint-inhibitor-gv20-0251-in-advanced-solid-tumors 2024-09-16T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diffuse-large-b-cell-lymphoma-is-curable-how-new-drug-polatuzumab-is-working-wonders 2024-09-16T07:50:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diffuse-large-b-cell-lymphoma-is-curable-how-new-drug-polatuzumab-is-working-wonders 2024-09-16T07:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-and-safety-of-pd-1-blockades-among-elderly-patients-with-p-dove-medical-press 2024-09-16T07:41:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/feasibility-and-safety-of-pd-1-blockades-among-elderly-patients-with-p-dove-medical-press 2024-09-16T07:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-finalizes-guidance-on-dose-optimization-for-oncology-therapies-clinical-leader 2024-09-16T07:41:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-finalizes-guidance-on-dose-optimization-for-oncology-therapies-clinical-leader 2024-09-16T07:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/roche-ocrevus-zunovo-approved-by-the-fda-marketscreener 2024-09-16T07:37:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-ocrevus-zunovo-approved-by-the-fda-marketscreener 2024-09-16T07:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-s-ebglyss-gains-approval-for-patients-12-years-and-older 2024-09-16T07:31:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-s-ebglyss-gains-approval-for-patients-12-years-and-older 2024-09-16T07:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-trop2-directed-adcs-show-promise-in-recurrent-gynecological-cancers 2024-09-16T07:21:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-trop2-directed-adcs-show-promise-in-recurrent-gynecological-cancers 2024-09-16T07:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T07:10:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T07:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-tigit-race-tightens-with-first-look-at-gsk-iteos-s-tigit-in-nsclc 2024-09-16T07:07:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-tigit-race-tightens-with-first-look-at-gsk-iteos-s-tigit-in-nsclc 2024-09-16T07:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/new-survey-reveals-12-of-americans-suffer-from-chronic-insomnia-as-sleep-health-concerns-rise 2024-09-16T07:06:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-survey-reveals-12-of-americans-suffer-from-chronic-insomnia-as-sleep-health-concerns-rise 2024-09-16T07:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/india-formalises-industry-partnerships-for-phase-one-clinical-trials-healthcare-asia 2024-09-16T06:59:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-formalises-industry-partnerships-for-phase-one-clinical-trials-healthcare-asia 2024-09-16T06:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/bavarian-nordic-s-mpox-vaccine-approved-by-who-medwatch 2024-09-16T06:56:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bavarian-nordic-s-mpox-vaccine-approved-by-who-medwatch 2024-09-16T06:56:04+00:00 weekly 0.7 https://trial.medpath.com/news/exact-sciences-colon-cancer-blood-test-shows-initial-promise-stat-news 2024-09-16T06:46:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exact-sciences-colon-cancer-blood-test-shows-initial-promise-stat-news 2024-09-16T06:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-pharmacy-times 2024-09-16T06:43:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-pharmacy-times 2024-09-16T06:43:32+00:00 weekly 0.7 https://trial.medpath.com/news/torl-biotherapeutics-presents-updated-phase-1-results-of-novel-claudin-6-targeted-biospace 2024-09-16T06:41:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/torl-biotherapeutics-presents-updated-phase-1-results-of-novel-claudin-6-targeted-biospace 2024-09-16T06:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-incyte-s-pd-1-treads-new-ground-in-anal-cancer-pharmaphorum 2024-09-16T06:37:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-incyte-s-pd-1-treads-new-ground-in-anal-cancer-pharmaphorum 2024-09-16T06:37:23+00:00 weekly 0.7 https://trial.medpath.com/news/erteilung-des-status-eines-therapiedurchbruchs-fur-sanbexin-sublingualtabletten-durch-die 2024-09-16T06:34:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/erteilung-des-status-eines-therapiedurchbruchs-fur-sanbexin-sublingualtabletten-durch-die 2024-09-16T06:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:34:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:32:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/l-agence-americaine-des-produits-alimentaires-et-medicamenteux-fda-accorde-pr-newswire 2024-09-16T06:26:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/l-agence-americaine-des-produits-alimentaires-et-medicamenteux-fda-accorde-pr-newswire 2024-09-16T06:26:51+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-ocrevus-zunovo-gets-fda-approval-to-treat-relapsing-and-progressive 2024-09-16T06:20:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-ocrevus-zunovo-gets-fda-approval-to-treat-relapsing-and-progressive 2024-09-16T06:20:39+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-as-biospace 2024-09-16T06:15:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-as-biospace 2024-09-16T06:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-biosimilar-landscape-growing-market-share-and-policy-changes-shape-future-access 2024-09-16T06:10:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-biosimilar-landscape-growing-market-share-and-policy-changes-shape-future-access 2024-09-16T06:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/keynote-006-study-of-pembrolizumab-shows-continued-survival-benefits-in-advanced-melanoma 2024-09-16T06:07:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keynote-006-study-of-pembrolizumab-shows-continued-survival-benefits-in-advanced-melanoma 2024-09-16T06:07:55+00:00 weekly 0.7 https://trial.medpath.com/news/bicycle-therapeutics-presents-updated-clinical-results-across-oncology-pipeline-at-esmo 2024-09-16T05:57:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bicycle-therapeutics-presents-updated-clinical-results-across-oncology-pipeline-at-esmo 2024-09-16T05:57:15+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T05:32:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T05:32:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute 2024-09-16T05:17:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute 2024-09-16T05:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/rybrevant-r-amivantamab-plus-chemotherapy-shows-positive-overall-survival-trend 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rybrevant-r-amivantamab-plus-chemotherapy-shows-positive-overall-survival-trend 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-eli-lilly-s-drug-for-eczema-express-pharma 2024-09-16T05:08:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-eli-lilly-s-drug-for-eczema-express-pharma 2024-09-16T05:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/rp1-nivolumab-combo-shows-durable-responses-favorable-safety-in-melanoma 2024-09-16T05:07:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rp1-nivolumab-combo-shows-durable-responses-favorable-safety-in-melanoma 2024-09-16T05:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/association-between-intensive-blood-pressure-lowering-and-stroke-free-survival-among 2024-09-16T05:07:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/association-between-intensive-blood-pressure-lowering-and-stroke-free-survival-among 2024-09-16T05:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-2024-2025-formula-covid-19-vaccine-available-at-major-pharmacies-across-the-u-s 2024-09-16T04:58:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-2024-2025-formula-covid-19-vaccine-available-at-major-pharmacies-across-the-u-s 2024-09-16T04:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/early-data-shows-mrna-4359-may-benefit-patients-with-advanced-solid-cancers 2024-09-16T04:38:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-data-shows-mrna-4359-may-benefit-patients-with-advanced-solid-cancers 2024-09-16T04:38:47+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-inc-latest-stock-news-market-updates 2024-09-16T04:29:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kura-oncology-inc-latest-stock-news-market-updates 2024-09-16T04:29:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-roche-s-tecentriq-hybreza-the-first-and-only-subcutaneous-anti-pd-l-cancer 2024-09-16T04:17:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-roche-s-tecentriq-hybreza-the-first-and-only-subcutaneous-anti-pd-l-cancer 2024-09-16T04:17:24+00:00 weekly 0.7 https://trial.medpath.com/news/5-late-stage-mrna-vaccines-to-watch-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-late-stage-mrna-vaccines-to-watch-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/dimerix-enters-key-collaboration-to-further-boost-action3-trial-recruitment-in-uk 2024-09-16T03:05:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dimerix-enters-key-collaboration-to-further-boost-action3-trial-recruitment-in-uk 2024-09-16T03:05:41+00:00 weekly 0.7 https://trial.medpath.com/news/remarkable-clinical-trial-results-shared-internationally-ansto 2024-09-16T02:16:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remarkable-clinical-trial-results-shared-internationally-ansto 2024-09-16T02:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-breakthrough-shared-globally-mirage-news 2024-09-16T02:13:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-breakthrough-shared-globally-mirage-news 2024-09-16T02:13:09+00:00 weekly 0.7 https://trial.medpath.com/news/booker-schmitt-paul-king-braun-whitehouse-kennedy-lujan-blumenthal-introduce-the 2024-09-16T01:21:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/booker-schmitt-paul-king-braun-whitehouse-kennedy-lujan-blumenthal-introduce-the 2024-09-16T01:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-maintains-qol-delays-pain-deterioration-in-hr-her2-low-ultralow-mbc 2024-09-16T01:12:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t-dxd-maintains-qol-delays-pain-deterioration-in-hr-her2-low-ultralow-mbc 2024-09-16T01:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/digital-support-app-launches-in-uk-to-address-rising-youth-cancer-cases 2024-09-16T01:07:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-support-app-launches-in-uk-to-address-rising-youth-cancer-cases 2024-09-16T01:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-anlotinib-and-penpulimab-gather-attention-in-hcc-with-apollo-results 2024-09-16T00:43:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-anlotinib-and-penpulimab-gather-attention-in-hcc-with-apollo-results 2024-09-16T00:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-updates-in-penile-cancer-urotoday 2024-09-16T00:40:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-updates-in-penile-cancer-urotoday 2024-09-16T00:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/who-approves-mpox-vaccine-for-babies-without-clinical-trials-the-conservative-woman 2024-09-16T00:38:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-approves-mpox-vaccine-for-babies-without-clinical-trials-the-conservative-woman 2024-09-16T00:38:37+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-dll-3-targeted-therapy-for-neuroendocrine-prostate-cancer-urotoday 2024-09-16T00:00:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-dll-3-targeted-therapy-for-neuroendocrine-prostate-cancer-urotoday 2024-09-16T00:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/ctdna-based-molecular-residual-disease-and-survival-in 2024-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ctdna-based-molecular-residual-disease-and-survival-in 2024-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-challenges-abbvie-s-serena-williams-ubrelvy-ad-for-misleading-migraine-claims 2024-09-15T23:49:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-challenges-abbvie-s-serena-williams-ubrelvy-ad-for-misleading-migraine-claims 2024-09-15T23:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/10-year-data-from-checkmate-067-confirms-survival-advantage-of-nivolumab-in-advanced 2024-09-15T23:44:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/10-year-data-from-checkmate-067-confirms-survival-advantage-of-nivolumab-in-advanced 2024-09-15T23:44:26+00:00 weekly 0.7 https://trial.medpath.com/news/sintilimab-combined-with-anlotinib-and-chemotherapy-as-second-line-or-later-therapy-in-nature 2024-09-15T23:30:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sintilimab-combined-with-anlotinib-and-chemotherapy-as-second-line-or-later-therapy-in-nature 2024-09-15T23:30:31+00:00 weekly 0.7 https://trial.medpath.com/news/radium-223-enhances-outcomes-with-enzalutamide-in-metastatic-castration-resistant 2024-09-15T23:00:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radium-223-enhances-outcomes-with-enzalutamide-in-metastatic-castration-resistant 2024-09-15T23:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/fecal-microbiota-transplant-boosts-immunotherapy-in-metastatic-renal-cell-carcinoma-in 2024-09-15T22:11:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fecal-microbiota-transplant-boosts-immunotherapy-in-metastatic-renal-cell-carcinoma-in 2024-09-15T22:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/azn-imfinzi-regimen-reduces-death-risk-by-25-in-late-stage-muscle-invasive 2024-09-15T22:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/azn-imfinzi-regimen-reduces-death-risk-by-25-in-late-stage-muscle-invasive 2024-09-15T22:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-approved-in-the-u-s-as-first-and-only-treatment-for-adolescents 2024-09-15T21:30:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-r-dupilumab-approved-in-the-u-s-as-first-and-only-treatment-for-adolescents 2024-09-15T21:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lilly-s-ebglysstm-lebrikizumab-lbkz-for-adults-and-children-12-years-and 2024-09-15T21:14:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lilly-s-ebglysstm-lebrikizumab-lbkz-for-adults-and-children-12-years-and 2024-09-15T21:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/torl-1-23-generates-responses-in-heavily-pretreated-cldn6-positive-solid-tumors 2024-09-15T21:07:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/torl-1-23-generates-responses-in-heavily-pretreated-cldn6-positive-solid-tumors 2024-09-15T21:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/liberty-cupid-study-c-confirms-benefit-of-dupilumab-in-biologic-naive-csu-hcplive 2024-09-15T21:07:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/liberty-cupid-study-c-confirms-benefit-of-dupilumab-in-biologic-naive-csu-hcplive 2024-09-15T21:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/news-from-esmo-an-astrazeneca-win-in-bladder-cancer-and-more 2024-09-15T21:02:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/news-from-esmo-an-astrazeneca-win-in-bladder-cancer-and-more 2024-09-15T21:02:04+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-expands-beyond-cancer-new-frontiers-in-autoimmune-disease-treatment 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-expands-beyond-cancer-new-frontiers-in-autoimmune-disease-treatment 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ich-updates-guidelines-ngs-becomes-new-standard-for-viral-safety-testing-in-biotech-manufacturing 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ich-updates-guidelines-ngs-becomes-new-standard-for-viral-safety-testing-in-biotech-manufacturing 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/systems-thinking-approach-could-revolutionize-clinical-trial-success-rates 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/systems-thinking-approach-could-revolutionize-clinical-trial-success-rates 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/radionuclide-containing-combo-slows-metastatic-prostate-cancer-improves-survival 2024-09-15T20:25:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radionuclide-containing-combo-slows-metastatic-prostate-cancer-improves-survival 2024-09-15T20:25:14+00:00 weekly 0.7 https://trial.medpath.com/news/cyramza-plus-lonsurf-did-not-improve-survival-in-metastatic-colorectal-cancer 2024-09-15T20:20:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cyramza-plus-lonsurf-did-not-improve-survival-in-metastatic-colorectal-cancer 2024-09-15T20:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/new-covid-vaccines-may-be-coming-to-australia-here-s-what-to-know-about-the-jn-1-shots 2024-09-15T20:14:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-covid-vaccines-may-be-coming-to-australia-here-s-what-to-know-about-the-jn-1-shots 2024-09-15T20:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/postsurgical-pembrolizumab-chemotherapy-misses-dfs-goal-in-endometrial-cancer 2024-09-15T20:12:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/postsurgical-pembrolizumab-chemotherapy-misses-dfs-goal-in-endometrial-cancer 2024-09-15T20:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T20:12:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T20:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/chemotherapy-de-escalation-associated-with-excellent-hr-her2-breast-cancer-survival 2024-09-15T19:35:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemotherapy-de-escalation-associated-with-excellent-hr-her2-breast-cancer-survival 2024-09-15T19:35:38+00:00 weekly 0.7 https://trial.medpath.com/news/splash-trial-highlights-radiopharmaceutical-lutetium-177-s-role-in-advanced-prostate 2024-09-15T19:32:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/splash-trial-highlights-radiopharmaceutical-lutetium-177-s-role-in-advanced-prostate 2024-09-15T19:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/no-smoking-startup-s-tiny-answer-to-safer-medical-cannabis-nocamels 2024-09-15T19:22:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/no-smoking-startup-s-tiny-answer-to-safer-medical-cannabis-nocamels 2024-09-15T19:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T19:13:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T19:13:53+00:00 weekly 0.7 https://trial.medpath.com/news/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study 2024-09-15T19:12:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study 2024-09-15T19:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-published-first-ever-efficacy-data-for-pd-1-vegf-bispecific-antibody-ivonescimab 2024-09-15T19:10:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-published-first-ever-efficacy-data-for-pd-1-vegf-bispecific-antibody-ivonescimab 2024-09-15T19:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/recent-health-headlines-fda-approvals-walgreens-settlement-and-more-devdiscourse 2024-09-15T19:03:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recent-health-headlines-fda-approvals-walgreens-settlement-and-more-devdiscourse 2024-09-15T19:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/retifanlimab-plus-carboplatin-and-paclitaxel-improve-pfs-in-recurrent-metastatic-anal-cancer 2024-09-15T19:02:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/retifanlimab-plus-carboplatin-and-paclitaxel-improve-pfs-in-recurrent-metastatic-anal-cancer 2024-09-15T19:02:29+00:00 weekly 0.7 https://trial.medpath.com/news/apple-s-airpods-pro-2-revolutionize-hearing-aid-tech-with-fda-approval 2024-09-15T19:02:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-s-airpods-pro-2-revolutionize-hearing-aid-tech-with-fda-approval 2024-09-15T19:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/atezolizumab-after-vemurafenib-and-cobimetinib-shows-trend-toward-better-os-in-melanoma 2024-09-15T18:59:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atezolizumab-after-vemurafenib-and-cobimetinib-shows-trend-toward-better-os-in-melanoma 2024-09-15T18:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/checkmate-77t-highlights-efs-benefit-in-perioperative-nivolumab-in-resectable-nsclc 2024-09-15T18:49:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/checkmate-77t-highlights-efs-benefit-in-perioperative-nivolumab-in-resectable-nsclc 2024-09-15T18:49:39+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-formalises-moas-with-multiple-sponsors-under-phase-one-clinical-trials-network 2024-09-15T18:31:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icmr-formalises-moas-with-multiple-sponsors-under-phase-one-clinical-trials-network 2024-09-15T18:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/early-switch-therapy-to-atezolizumab-after-vemurafenib-cobimetinib-run-in-improves-os 2024-09-15T18:31:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-switch-therapy-to-atezolizumab-after-vemurafenib-cobimetinib-run-in-improves-os 2024-09-15T18:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/extended-follow-up-shows-dfs-benefit-for-pembrolizumab-in-miuc-urology-times 2024-09-15T17:58:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/extended-follow-up-shows-dfs-benefit-for-pembrolizumab-in-miuc-urology-times 2024-09-15T17:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/radiation-therapy-for-women-with-breast-cancer-will-now-last-for-no-more-than-three-weeks 2024-09-15T17:54:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiation-therapy-for-women-with-breast-cancer-will-now-last-for-no-more-than-three-weeks 2024-09-15T17:54:34+00:00 weekly 0.7 https://trial.medpath.com/news/missed-out-on-viking-therapeutics-buy-this-weight-loss-biotech-stock-right-now 2024-09-15T17:42:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/missed-out-on-viking-therapeutics-buy-this-weight-loss-biotech-stock-right-now 2024-09-15T17:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/incremental-effectiveness-costs-may-improve-using-biomarker-guided-selection 2024-09-15T17:31:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incremental-effectiveness-costs-may-improve-using-biomarker-guided-selection 2024-09-15T17:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/os-increase-observed-in-neoadjuvant-pembrolizumab-combo-plus-adjuvant-therapy-in-early-tnbc 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/os-increase-observed-in-neoadjuvant-pembrolizumab-combo-plus-adjuvant-therapy-in-early-tnbc 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-combo-shows-dfs-benefit-in-dmmr-endometrial-cancer-subgroup 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-combo-shows-dfs-benefit-in-dmmr-endometrial-cancer-subgroup 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/queen-mary-university-of-london-researchers-announce-ground-breaking-clinical-trial 2024-09-15T17:16:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/queen-mary-university-of-london-researchers-announce-ground-breaking-clinical-trial 2024-09-15T17:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-chemo-adjuvant-pembrolizumab-boosts-os-in-early-tnbc 2024-09-15T17:12:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-pembrolizumab-chemo-adjuvant-pembrolizumab-boosts-os-in-early-tnbc 2024-09-15T17:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/enhanced-progression-free-survival-with-retifanlimab-carboplatin-and-paclitaxel-in 2024-09-15T17:03:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enhanced-progression-free-survival-with-retifanlimab-carboplatin-and-paclitaxel-in 2024-09-15T17:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approvals-fraud-settlements-and-global-health-initiatives-latest-health-news 2024-09-15T16:57:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approvals-fraud-settlements-and-global-health-initiatives-latest-health-news 2024-09-15T16:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/doh-6-warns-public-on-unauthorized-mpox-vaccines-daily-guardian 2024-09-15T16:55:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doh-6-warns-public-on-unauthorized-mpox-vaccines-daily-guardian 2024-09-15T16:55:56+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-reveal-breakthrough-in-hard-to-treat-cancers-mirage-news 2024-09-15T16:49:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-reveal-breakthrough-in-hard-to-treat-cancers-mirage-news 2024-09-15T16:49:22+00:00 weekly 0.7 https://trial.medpath.com/news/queen-mary-university-of-london-researchers-announce-ground-breaking-trial-results-for 2024-09-15T16:48:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/queen-mary-university-of-london-researchers-announce-ground-breaking-trial-results-for 2024-09-15T16:48:00+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-keynote-006-data-support-pembrolizumab-as-soc-in-advanced-melanoma 2024-09-15T16:35:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-keynote-006-data-support-pembrolizumab-as-soc-in-advanced-melanoma 2024-09-15T16:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/olaparib-cediranib-misses-survival-end-points-in-relapsed-ovarian-cancer-trial-onclive 2024-09-15T16:22:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olaparib-cediranib-misses-survival-end-points-in-relapsed-ovarian-cancer-trial-onclive 2024-09-15T16:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-tar-200-phase-2b-sunrise-1-study-shows-84-complete-response-in-high-risk 2024-09-15T15:47:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-tar-200-phase-2b-sunrise-1-study-shows-84-complete-response-in-high-risk 2024-09-15T15:47:33+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-enhertu-to-eclipse-soc-for-her2-breast-cancer-with-brain-metastases 2024-09-15T15:23:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-enhertu-to-eclipse-soc-for-her2-breast-cancer-with-brain-metastases 2024-09-15T15:23:01+00:00 weekly 0.7 https://trial.medpath.com/news/medilink-presents-yl201-b7h3-adc-at-esmo-2024-with-over-6-months-pfs-in-sclc 2024-09-15T15:16:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medilink-presents-yl201-b7h3-adc-at-esmo-2024-with-over-6-months-pfs-in-sclc 2024-09-15T15:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunotherapy-superior-to-targeted-therapy-in-stage-iii-melanoma 2024-09-15T15:10:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-immunotherapy-superior-to-targeted-therapy-in-stage-iii-melanoma 2024-09-15T15:10:18+00:00 weekly 0.7 https://trial.medpath.com/news/from-patient-to-entrepreneur-edmond-woman-creates-medical-device-kokh 2024-09-15T14:52:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/from-patient-to-entrepreneur-edmond-woman-creates-medical-device-kokh 2024-09-15T14:52:03+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-gsk-iteos-bring-some-optimism-back-to-tigit-pharmaphorum 2024-09-15T14:46:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-gsk-iteos-bring-some-optimism-back-to-tigit-pharmaphorum 2024-09-15T14:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:46:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:46:26+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:44:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:43:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-tecentriq-avastin-s-prospects-as-the-first-hcc-adjuvant-therapy-fade 2024-09-15T14:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-tecentriq-avastin-s-prospects-as-the-first-hcc-adjuvant-therapy-fade 2024-09-15T14:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-15T14:34:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-15T14:34:34+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:31:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/roswell-park-designed-treatment-regimen-doubles-progression-free-survival-in 2024-09-15T14:25:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roswell-park-designed-treatment-regimen-doubles-progression-free-survival-in 2024-09-15T14:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/prince-trial-highlights-early-detection-of-prostate-cancer-progression-with-psma-pet-ct 2024-09-15T14:20:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prince-trial-highlights-early-detection-of-prostate-cancer-progression-with-psma-pet-ct 2024-09-15T14:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/disitamab-vedotin-promising-her2-targeted-therapy-for-urothelial-cancer-matthew-galsky 2024-09-15T14:14:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disitamab-vedotin-promising-her2-targeted-therapy-for-urothelial-cancer-matthew-galsky 2024-09-15T14:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/first-cancer-medicine-decision-following-pharmac-funding-boost-scoop-news 2024-09-15T14:10:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-cancer-medicine-decision-following-pharmac-funding-boost-scoop-news 2024-09-15T14:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/3d-systems-smith-nephew-announce-fda-clearance-for-total-ankle-replacement-solution 2024-09-15T14:06:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3d-systems-smith-nephew-announce-fda-clearance-for-total-ankle-replacement-solution 2024-09-15T14:06:58+00:00 weekly 0.7 https://trial.medpath.com/news/rybrevant-r-amivantamab-vmjw-plus-chemotherapy-show-49-percent-overall-response 2024-09-15T14:06:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rybrevant-r-amivantamab-vmjw-plus-chemotherapy-show-49-percent-overall-response 2024-09-15T14:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/weekend-icymi-september-9-to-september-13-drug-topics 2024-09-15T14:04:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekend-icymi-september-9-to-september-13-drug-topics 2024-09-15T14:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T13:59:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T13:59:55+00:00 weekly 0.7 https://trial.medpath.com/news/dr-angeles-alvarez-secord-on-exciting-responses-with-mirvetuximab-soravtansine-in 2024-09-15T13:55:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-angeles-alvarez-secord-on-exciting-responses-with-mirvetuximab-soravtansine-in 2024-09-15T13:55:52+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-primary-analysis-data-from-ignyte-globenewswire 2024-09-15T13:49:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-presents-primary-analysis-data-from-ignyte-globenewswire 2024-09-15T13:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/high-dose-vitamin-d3-does-not-provide-benefit-for-metastatic-colorectal-cancer 2024-09-15T13:49:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-dose-vitamin-d3-does-not-provide-benefit-for-metastatic-colorectal-cancer 2024-09-15T13:49:21+00:00 weekly 0.7 https://trial.medpath.com/news/ambassador-trial-extended-follow-up-on-adjuvant-pembrolizumab-in-bladder-cancer 2024-09-15T13:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ambassador-trial-extended-follow-up-on-adjuvant-pembrolizumab-in-bladder-cancer 2024-09-15T13:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/scorpion-therapeutics-presents-initial-clinical-data-from-its-phase-1-2-trial-of-stx-478-kxra 2024-09-15T13:32:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scorpion-therapeutics-presents-initial-clinical-data-from-its-phase-1-2-trial-of-stx-478-kxra 2024-09-15T13:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/the-dav132-colon-targeted-adsorbent-does-not-interfere-with-plasma-concentrations-of-nature 2024-09-15T13:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-dav132-colon-targeted-adsorbent-does-not-interfere-with-plasma-concentrations-of-nature 2024-09-15T13:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/who-prequalifies-a-mpox-vaccine-clearing-path-to-access-contagion-live 2024-09-15T13:28:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-prequalifies-a-mpox-vaccine-clearing-path-to-access-contagion-live 2024-09-15T13:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study-of-vobra 2024-09-15T13:24:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study-of-vobra 2024-09-15T13:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-presents-landmark-10-year-follow-up-data-from-checkmate-morningstar 2024-09-15T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-presents-landmark-10-year-follow-up-data-from-checkmate-morningstar 2024-09-15T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/oncternal-therapeutics-axes-b-cell-lymphoma-trial-for-car-t-therapy-onct-808 2024-09-15T13:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncternal-therapeutics-axes-b-cell-lymphoma-trial-for-car-t-therapy-onct-808 2024-09-15T13:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/apple-gets-fda-approval-for-airpods-pro-2-hearing-aid-feature-here-is-how-it-can-help-people 2024-09-15T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-gets-fda-approval-for-airpods-pro-2-hearing-aid-feature-here-is-how-it-can-help-people 2024-09-15T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy-newsroom 2024-09-15T13:01:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy-newsroom 2024-09-15T13:01:07+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-stock-titan 2024-09-15T12:59:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-stock-titan 2024-09-15T12:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:57:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-yahoo-finance 2024-09-15T12:56:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-yahoo-finance 2024-09-15T12:56:57+00:00 weekly 0.7 https://trial.medpath.com/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:56:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy 2024-09-15T12:52:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy 2024-09-15T12:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-provides-update-on-contact-02-phase-iii-trial-in-metastatic-castration-resistant 2024-09-15T12:52:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipsen-provides-update-on-contact-02-phase-iii-trial-in-metastatic-castration-resistant 2024-09-15T12:52:13+00:00 weekly 0.7 https://trial.medpath.com/news/ten-year-data-for-merck-s-keytruda-r-pembrolizumab-demonstrates-sustained-overall 2024-09-15T12:50:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ten-year-data-for-merck-s-keytruda-r-pembrolizumab-demonstrates-sustained-overall 2024-09-15T12:50:32+00:00 weekly 0.7 https://trial.medpath.com/news/ds-9606-shows-promising-preliminary-clinical-activity-in-patients-with-advanced-solid-tumors 2024-09-15T12:50:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ds-9606-shows-promising-preliminary-clinical-activity-in-patients-with-advanced-solid-tumors 2024-09-15T12:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-globenewswire 2024-09-15T12:39:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-globenewswire 2024-09-15T12:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-percent-complete-response 2024-09-15T12:30:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-percent-complete-response 2024-09-15T12:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-pembrolizumab-and-tace-demonstrate-significant-progression-free-survival 2024-09-15T11:08:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenvatinib-pembrolizumab-and-tace-demonstrate-significant-progression-free-survival 2024-09-15T11:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-pulse-quiz-september-15 2024-09-15T11:04:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeted-pulse-quiz-september-15 2024-09-15T11:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/khcc-achieves-breakthrough-in-cancer-treatment-using-modified-t-lymphocytes 2024-09-15T10:31:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/khcc-achieves-breakthrough-in-cancer-treatment-using-modified-t-lymphocytes 2024-09-15T10:31:48+00:00 weekly 0.7 https://trial.medpath.com/news/retina-society-2024-advances-in-amd-therapy-highlight-different-mechanisms-of-action-with 2024-09-15T10:17:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/retina-society-2024-advances-in-amd-therapy-highlight-different-mechanisms-of-action-with 2024-09-15T10:17:30+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-esmo-2024-globenewswire 2024-09-15T10:07:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precede-biosciences-presents-new-data-at-esmo-2024-globenewswire 2024-09-15T10:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/no-survival-gain-with-preoperative-crt-plus-perioperative-chemo-for-gastric-cancer 2024-09-15T09:59:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/no-survival-gain-with-preoperative-crt-plus-perioperative-chemo-for-gastric-cancer 2024-09-15T09:59:47+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-pharmacist-advocates-for-evidence-based-cannabis-discussions-in-cancer-care 2024-09-15T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-pharmacist-advocates-for-evidence-based-cannabis-discussions-in-cancer-care 2024-09-15T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-nivolumab-and-relatlimab-in-locally-advanced-mmr-deficient-colon-cancer 2024-09-15T07:45:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-nivolumab-and-relatlimab-in-locally-advanced-mmr-deficient-colon-cancer 2024-09-15T07:45:33+00:00 weekly 0.7 https://trial.medpath.com/news/23andme-therapeutics-announces-phase-2-results-for-two-additional-cancer-cohorts-and 2024-09-15T07:25:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/23andme-therapeutics-announces-phase-2-results-for-two-additional-cancer-cohorts-and 2024-09-15T07:25:18+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-chiefs-to-roll-out-new-drugs-for-lethal-lung-disease-that-took-life-of-star-trek-actor 2024-09-15T05:48:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-chiefs-to-roll-out-new-drugs-for-lethal-lung-disease-that-took-life-of-star-trek-actor 2024-09-15T05:48:55+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-quality-gap-in-online-psoriasis-treatment-information-sources 2024-09-15T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-quality-gap-in-online-psoriasis-treatment-information-sources 2024-09-15T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/retina-society-2024-first-time-phase-2-clinical-trial-results-for-onl-1204-for 2024-09-15T04:10:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/retina-society-2024-first-time-phase-2-clinical-trial-results-for-onl-1204-for 2024-09-15T04:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-as-scientists-develop-cancer-killing-treatment-that-preserves-healthy-body-cells 2024-09-15T01:07:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-as-scientists-develop-cancer-killing-treatment-that-preserves-healthy-body-cells 2024-09-15T01:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/novel-agents-and-promising-combinations-in-urothelial-and-renal-cell-carcinoma-urotoday 2024-09-15T00:51:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-agents-and-promising-combinations-in-urothelial-and-renal-cell-carcinoma-urotoday 2024-09-15T00:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-shows-promise-for-maralixibat-in-treating-algs-related-cholestatic-pruritus 2024-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-shows-promise-for-maralixibat-in-treating-algs-related-cholestatic-pruritus 2024-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-dr-jonasch-on-implications-of-positive-hif-2a-inhibitor-data-in-ccrcc 2024-09-14T23:10:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-dr-jonasch-on-implications-of-positive-hif-2a-inhibitor-data-in-ccrcc 2024-09-14T23:10:34+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-shows-comparable-outcomes-between-ct-p13-remicade-in-ra 2024-09-14T23:03:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-study-shows-comparable-outcomes-between-ct-p13-remicade-in-ra 2024-09-14T23:03:21+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-pharmaceuticals-presented-two-positive-clinical-results-of-once-weekly-insulin 2024-09-14T23:00:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gan-lee-pharmaceuticals-presented-two-positive-clinical-results-of-once-weekly-insulin 2024-09-14T23:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/ipilimumab-nivolumab-significantly-improves-12-month-nccrcc-survival-in-sunniforecast 2024-09-14T22:01:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipilimumab-nivolumab-significantly-improves-12-month-nccrcc-survival-in-sunniforecast 2024-09-14T22:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-heart-valve-technology-could-improve-patient-lives-news-medical 2024-09-14T21:50:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-heart-valve-technology-could-improve-patient-lives-news-medical 2024-09-14T21:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/enfortumab-vedotin-effective-in-patients-with-urothelial-cancer-outside-of-clinical-trials 2024-09-14T21:26:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enfortumab-vedotin-effective-in-patients-with-urothelial-cancer-outside-of-clinical-trials 2024-09-14T21:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/united-states-remote-climate-control-market-by-application-2024-2031-third-eye-news 2024-09-14T21:17:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/united-states-remote-climate-control-market-by-application-2024-2031-third-eye-news 2024-09-14T21:17:36+00:00 weekly 0.7 https://trial.medpath.com/news/andrea-banty-np-dnp-navigating-new-developments-in-ibd-therapeutics-hcplive 2024-09-14T21:15:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/andrea-banty-np-dnp-navigating-new-developments-in-ibd-therapeutics-hcplive 2024-09-14T21:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-test-firm-oncologica-looking-to-raise-cash-this-is-money 2024-09-14T20:56:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-test-firm-oncologica-looking-to-raise-cash-this-is-money 2024-09-14T20:56:52+00:00 weekly 0.7 https://trial.medpath.com/news/retifanlimab-plus-carboplatin-meets-pfs-end-point-in-metastatic-scac-cancer-network 2024-09-14T20:31:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/retifanlimab-plus-carboplatin-meets-pfs-end-point-in-metastatic-scac-cancer-network 2024-09-14T20:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-radium-223-to-enzalutamide-significantly-improves-rpfs-and-os-in-mcrpc 2024-09-14T20:18:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-radium-223-to-enzalutamide-significantly-improves-rpfs-and-os-in-mcrpc 2024-09-14T20:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/safety-activity-seen-with-frontline-zanidatamab-plus-chemo-bevacizumab-in-her2-mcrc 2024-09-14T20:04:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-activity-seen-with-frontline-zanidatamab-plus-chemo-bevacizumab-in-her2-mcrc 2024-09-14T20:04:59+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-drug-may-lower-death-rate-in-obese-people-study-the-hindu 2024-09-14T20:00:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diabetes-drug-may-lower-death-rate-in-obese-people-study-the-hindu 2024-09-14T20:00:17+00:00 weekly 0.7 https://trial.medpath.com/news/zipalertinib-shows-promise-in-heavily-pretreated-egfr-exon-20-mutated-nsclc 2024-09-14T19:23:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zipalertinib-shows-promise-in-heavily-pretreated-egfr-exon-20-mutated-nsclc 2024-09-14T19:23:56+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-pembrolizumab-chemotherapy-fails-to-improve-dfs-high-risk-endometrial-cancer 2024-09-14T19:03:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-pembrolizumab-chemotherapy-fails-to-improve-dfs-high-risk-endometrial-cancer 2024-09-14T19:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/first-of-its-kind-colorectal-cancer-data-from-prospective-galaxy-study-released-at-esmo 2024-09-14T18:31:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-of-its-kind-colorectal-cancer-data-from-prospective-galaxy-study-released-at-esmo 2024-09-14T18:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/encorafenib-binimetinib-exhibits-anti-tumor-activity-in-untreated-braf-mutant-advanced-nsclc 2024-09-14T18:24:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/encorafenib-binimetinib-exhibits-anti-tumor-activity-in-untreated-braf-mutant-advanced-nsclc 2024-09-14T18:24:44+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-dato-dxd-plus-durvalumab-shows-variable-pcr-rates-in-stage-ii-iii-breast-cancer 2024-09-14T18:07:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-dato-dxd-plus-durvalumab-shows-variable-pcr-rates-in-stage-ii-iii-breast-cancer 2024-09-14T18:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-invited-discussant-optimizing-post-io-therapy-in-clear-cell-rcc-and 2024-09-14T17:41:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-invited-discussant-optimizing-post-io-therapy-in-clear-cell-rcc-and 2024-09-14T17:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-s-karxt-faces-fda-approval-hurdles-analyst-issues-sell-rating-amid 2024-09-14T17:26:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-karxt-faces-fda-approval-hurdles-analyst-issues-sell-rating-amid 2024-09-14T17:26:42+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-t-dxd-combinations-show-early-antitumor-activity-in-her2-gastric-gej-cancers 2024-09-14T17:09:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-line-t-dxd-combinations-show-early-antitumor-activity-in-her2-gastric-gej-cancers 2024-09-14T17:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/study-ev-103-dose-escalation-cohort-a-5y-follow-up-of-first-line-enfortumab-vedotin 2024-09-14T16:53:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-ev-103-dose-escalation-cohort-a-5y-follow-up-of-first-line-enfortumab-vedotin 2024-09-14T16:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/tigit-drug-from-iteos-shrinks-lung-tumors-in-trial-biopharma-dive 2024-09-14T16:51:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tigit-drug-from-iteos-shrinks-lung-tumors-in-trial-biopharma-dive 2024-09-14T16:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/rybrevant-shows-colorectal-cancer-promise-in-latest-bispecifics-win-biocentury 2024-09-14T16:46:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rybrevant-shows-colorectal-cancer-promise-in-latest-bispecifics-win-biocentury 2024-09-14T16:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-aortic-valve-replacement-on-myocardial-perfusion-and-exercise-capacity-in-patients 2024-09-14T16:39:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-aortic-valve-replacement-on-myocardial-perfusion-and-exercise-capacity-in-patients 2024-09-14T16:39:21+00:00 weekly 0.7 https://trial.medpath.com/news/data-support-pembrolizumab-regimen-as-new-standard-for-advanced-cervical-cancer 2024-09-14T16:39:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-support-pembrolizumab-regimen-as-new-standard-for-advanced-cervical-cancer 2024-09-14T16:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/colorado-researcher-says-people-with-ptsd-are-losing-out-on-an-effective-treatment 2024-09-14T16:02:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/colorado-researcher-says-people-with-ptsd-are-losing-out-on-an-effective-treatment 2024-09-14T16:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/bl-b01d1-shows-favorable-phase-2-efficacy-safety-for-urothelial-carcinoma-urology-times 2024-09-14T15:01:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bl-b01d1-shows-favorable-phase-2-efficacy-safety-for-urothelial-carcinoma-urology-times 2024-09-14T15:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/checkpoint-inhibitor-staves-off-disease-progression-in-anal-cancer-trial-stat-news 2024-09-14T14:48:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/checkpoint-inhibitor-staves-off-disease-progression-in-anal-cancer-trial-stat-news 2024-09-14T14:48:00+00:00 weekly 0.7 https://trial.medpath.com/news/keytruda-r-pembrolizumab-plus-lenvima-r-lenvatinib-in-combination-with 2024-09-14T14:39:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keytruda-r-pembrolizumab-plus-lenvima-r-lenvatinib-in-combination-with 2024-09-14T14:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-r-pembrolizumab-plus-chemoradiotherapy-crt-reduced-risk-of 2024-09-14T14:33:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-keytruda-r-pembrolizumab-plus-chemoradiotherapy-crt-reduced-risk-of 2024-09-14T14:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/niktimvo-for-the-treatment-of-cgvhd-us-clinical-trials-arena 2024-09-14T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/niktimvo-for-the-treatment-of-cgvhd-us-clinical-trials-arena 2024-09-14T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-14T13:40:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-14T13:40:20+00:00 weekly 0.7 https://trial.medpath.com/news/company-statement-on-fda-advisory-committee-meeting-biospace 2024-09-14T13:14:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/company-statement-on-fda-advisory-committee-meeting-biospace 2024-09-14T13:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-to-advance-1st-in-human-trials-for-zika-flu-blood-cancer-therapies-health-news 2024-09-14T12:38:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icmr-to-advance-1st-in-human-trials-for-zika-flu-blood-cancer-therapies-health-news 2024-09-14T12:38:54+00:00 weekly 0.7 https://trial.medpath.com/news/gut-microbiome-emerges-as-key-player-in-cancer-immunotherapy-response-new-research-shows 2024-09-14T12:35:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gut-microbiome-emerges-as-key-player-in-cancer-immunotherapy-response-new-research-shows 2024-09-14T12:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/maui-derm-np-pa-fall-2024-conference-to-spotlight-latest-advances-in-dermatology-treatment 2024-09-14T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maui-derm-np-pa-fall-2024-conference-to-spotlight-latest-advances-in-dermatology-treatment 2024-09-14T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-jonathan-riess-on-the-potential-of-io102-io103-the-cancer-vaccine-landscape 2024-09-14T11:37:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-jonathan-riess-on-the-potential-of-io102-io103-the-cancer-vaccine-landscape 2024-09-14T11:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-new-leadership-and-groundbreaking-developments-in-oncology-research-and-patient-care 2024-09-14T11:17:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-new-leadership-and-groundbreaking-developments-in-oncology-research-and-patient-care 2024-09-14T11:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/experts-highlight-new-dermatological-treatments-importance-of-clinical-trial-diversity 2024-09-14T11:06:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-highlight-new-dermatological-treatments-importance-of-clinical-trial-diversity 2024-09-14T11:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-alzheimer-s-drug-to-slow-disease-progression-nbc26 2024-09-14T10:59:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-alzheimer-s-drug-to-slow-disease-progression-nbc26 2024-09-14T10:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/what-happened-in-optometry-this-week-september-9 2024-09-14T10:30:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-happened-in-optometry-this-week-september-9 2024-09-14T10:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/ocudyne-completes-successful-pilot-study-of-optic-system-ophthalmology-times 2024-09-14T10:18:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocudyne-completes-successful-pilot-study-of-optic-system-ophthalmology-times 2024-09-14T10:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/correction-to-eli-lilly-gets-fda-approval-for-eczema-treatment-article-morningstar 2024-09-14T10:15:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/correction-to-eli-lilly-gets-fda-approval-for-eczema-treatment-article-morningstar 2024-09-14T10:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/less-toxic-cancer-therapies-for-healthier-lives-featured-research-seattle-children-s 2024-09-14T09:45:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/less-toxic-cancer-therapies-for-healthier-lives-featured-research-seattle-children-s 2024-09-14T09:45:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-updates-warning-for-liver-injury-due-to-fezolinetant-contemporary-ob-gyn 2024-09-14T09:23:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-updates-warning-for-liver-injury-due-to-fezolinetant-contemporary-ob-gyn 2024-09-14T09:23:50+00:00 weekly 0.7 https://trial.medpath.com/news/nuvation-bio-announces-positive-pooled-data-from-the-pivotal-phase-2-trust-i-marketscreener 2024-09-14T08:11:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuvation-bio-announces-positive-pooled-data-from-the-pivotal-phase-2-trust-i-marketscreener 2024-09-14T08:11:21+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-reduces-all-cause-mortality-greater-than-a-bispecific-antibody-in-mm 2024-09-14T08:09:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-reduces-all-cause-mortality-greater-than-a-bispecific-antibody-in-mm 2024-09-14T08:09:17+00:00 weekly 0.7 https://trial.medpath.com/news/immunocore-holdings-plc-american-depositary-shares-imcr-stock-news 2024-09-14T08:03:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunocore-holdings-plc-american-depositary-shares-imcr-stock-news 2024-09-14T08:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination 2024-09-14T07:46:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination 2024-09-14T07:46:58+00:00 weekly 0.7 https://trial.medpath.com/news/acrivon-therapeutics-reports-positive-endometrial-cancer-data-from-ongoing-acr-368 2024-09-14T07:20:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acrivon-therapeutics-reports-positive-endometrial-cancer-data-from-ongoing-acr-368 2024-09-14T07:20:57+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-friday-5-september-13-2024 2024-09-14T07:05:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-friday-5-september-13-2024 2024-09-14T07:05:10+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-biospace 2024-09-14T06:54:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-biospace 2024-09-14T06:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/prelude-therapeutics-smarca2-degrader-prt3789-demonstrated-promising-initial-biospace 2024-09-14T06:54:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prelude-therapeutics-smarca2-degrader-prt3789-demonstrated-promising-initial-biospace 2024-09-14T06:54:03+00:00 weekly 0.7 https://trial.medpath.com/news/bms-immunotherapy-hits-in-lung-cancer-advancing-to-phase-3-stat-news 2024-09-14T06:53:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bms-immunotherapy-hits-in-lung-cancer-advancing-to-phase-3-stat-news 2024-09-14T06:53:07+00:00 weekly 0.7 https://trial.medpath.com/news/oneoncology-cmo-highlights-critical-role-of-real-world-evidence-in-precision-medicine-testing 2024-09-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oneoncology-cmo-highlights-critical-role-of-real-world-evidence-in-precision-medicine-testing 2024-09-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncternal-stock-crashes-by-60-as-it-lays-off-staff-and-scraps-trials 2024-09-14T05:46:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncternal-stock-crashes-by-60-as-it-lays-off-staff-and-scraps-trials 2024-09-14T05:46:41+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-bms-986012-plus-nivolumab-chemotherapy-shows-promise-in-es-sclc 2024-09-14T05:08:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontline-bms-986012-plus-nivolumab-chemotherapy-shows-promise-in-es-sclc 2024-09-14T05:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/nutrition-remains-critical-in-mash-management-despite-new-drug-approval-experts-emphasize 2024-09-14T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nutrition-remains-critical-in-mash-management-despite-new-drug-approval-experts-emphasize 2024-09-14T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lilly-s-ebglysstm-lebrikizumab-lbkz-for-adults-and-children-12-years-and 2024-09-14T00:33:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lilly-s-ebglysstm-lebrikizumab-lbkz-for-adults-and-children-12-years-and 2024-09-14T00:33:25+00:00 weekly 0.7 https://trial.medpath.com/news/3-biotech-ipos-703m-raised-for-clinical-trials-in-cancer-immunology-endocrine-disorders 2024-09-14T00:30:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-biotech-ipos-703m-raised-for-clinical-trials-in-cancer-immunology-endocrine-disorders 2024-09-14T00:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/japan-s-ministry-of-health-labor-and-welfare-approves-csl-and-arcturus-therapeutics 2024-09-14T00:16:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/japan-s-ministry-of-health-labor-and-welfare-approves-csl-and-arcturus-therapeutics 2024-09-14T00:16:23+00:00 weekly 0.7 https://trial.medpath.com/news/belzutifan-yields-sustained-responses-pfs-in-advanced-clear-cell-rcc-cancer-network 2024-09-14T00:08:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belzutifan-yields-sustained-responses-pfs-in-advanced-clear-cell-rcc-cancer-network 2024-09-14T00:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/digital-medicine-support-models-tested-for-alcohol-use-disorder 2024-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-medicine-support-models-tested-for-alcohol-use-disorder 2024-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/how-to-optimise-treatment-in-egfr-mutant-nsclc 2024-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-to-optimise-treatment-in-egfr-mutant-nsclc 2024-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/darolutamide-in-addition-to-adt-versus-adt-in-metastatic-hormone-sensitive-prostate-urotoday 2024-09-13T23:07:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/darolutamide-in-addition-to-adt-versus-adt-in-metastatic-hormone-sensitive-prostate-urotoday 2024-09-13T23:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/gadgeel-s-preview-of-key-esmo-2024-findings-in-lung-cancer-targeted-oncology 2024-09-13T23:03:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gadgeel-s-preview-of-key-esmo-2024-findings-in-lung-cancer-targeted-oncology 2024-09-13T23:03:56+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-durvalumab-fails-to-boost-dfs-in-resected-nsclc-irrespective-of-pd-l1-status 2024-09-13T21:31:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-durvalumab-fails-to-boost-dfs-in-resected-nsclc-irrespective-of-pd-l1-status 2024-09-13T21:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-tecentriq-gets-fda-ok-gilead-shot-succeeds-in-second-hiv-trial 2024-09-13T21:28:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/subcutaneous-tecentriq-gets-fda-ok-gilead-shot-succeeds-in-second-hiv-trial 2024-09-13T21:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-presents-updated-phase-1-2-masofaniten-epi-7386-clinical-data-at-the 2024-09-13T21:21:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essa-pharma-presents-updated-phase-1-2-masofaniten-epi-7386-clinical-data-at-the 2024-09-13T21:21:52+00:00 weekly 0.7 https://trial.medpath.com/news/beyond-celiac-accelerates-search-for-celiac-disease-cure-by-2030-benzinga 2024-09-13T21:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beyond-celiac-accelerates-search-for-celiac-disease-cure-by-2030-benzinga 2024-09-13T21:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/arizona-liver-health-arizona-clinical-trials-celebrates-the-grand-opening-of-act-medical-park 2024-09-13T20:20:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arizona-liver-health-arizona-clinical-trials-celebrates-the-grand-opening-of-act-medical-park 2024-09-13T20:20:31+00:00 weekly 0.7 https://trial.medpath.com/news/a-pde4b-inhibitor-with-demonstrated-clinical-potential-in-treating-ipf 2024-09-13T20:14:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-pde4b-inhibitor-with-demonstrated-clinical-potential-in-treating-ipf 2024-09-13T20:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/two-organizations-partner-to-develop-research-on-veterinary-device-for-osteoarthitis 2024-09-13T20:12:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-organizations-partner-to-develop-research-on-veterinary-device-for-osteoarthitis 2024-09-13T20:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/mercks-irreversible-lsd1-inhibitor-for-mpns 2024-09-13T19:57:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mercks-irreversible-lsd1-inhibitor-for-mpns 2024-09-13T19:57:43+00:00 weekly 0.7 https://trial.medpath.com/news/a-dual-5-ht2a-and-5-ht2c-receptor-inverse-agonist-developed-to-address-the-limitations-of-pimavanserin 2024-09-13T19:51:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-dual-5-ht2a-and-5-ht2c-receptor-inverse-agonist-developed-to-address-the-limitations-of-pimavanserin 2024-09-13T19:51:25+00:00 weekly 0.7 https://trial.medpath.com/news/consolidation-durvalumab-consistently-improves-pfs-os-in-ls-sclc-subgroups 2024-09-13T19:50:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/consolidation-durvalumab-consistently-improves-pfs-os-in-ls-sclc-subgroups 2024-09-13T19:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-potent-zwitterionic-inhibitor-of-khk 2024-09-13T19:40:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-potent-zwitterionic-inhibitor-of-khk 2024-09-13T19:40:32+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-announces-four-abstracts-accepted-for-presentation-at-the-european-society-biospace 2024-09-13T19:40:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempus-announces-four-abstracts-accepted-for-presentation-at-the-european-society-biospace 2024-09-13T19:40:15+00:00 weekly 0.7 https://trial.medpath.com/news/a-cbd-analogue-and-gpr55-antagonist-for-neuropathic-pain 2024-09-13T19:31:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-cbd-analogue-and-gpr55-antagonist-for-neuropathic-pain 2024-09-13T19:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/press-releases-friday-sep-13-2024-genentech 2024-09-13T18:21:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-releases-friday-sep-13-2024-genentech 2024-09-13T18:21:03+00:00 weekly 0.7 https://trial.medpath.com/news/cabozantinib-nivolumab-combination-findings-further-inform-rcc-care-onclive 2024-09-13T18:03:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cabozantinib-nivolumab-combination-findings-further-inform-rcc-care-onclive 2024-09-13T18:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-a-new-medically-promising-antibody-conjugate-for-metastatic-breast-cancer 2024-09-13T17:59:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-a-new-medically-promising-antibody-conjugate-for-metastatic-breast-cancer 2024-09-13T17:59:38+00:00 weekly 0.7 https://trial.medpath.com/news/tivozanib-monotherapy-bests-lower-dose-tivozanib-plus-nivolumab-in-metastatic-rcc-onclive 2024-09-13T17:54:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tivozanib-monotherapy-bests-lower-dose-tivozanib-plus-nivolumab-in-metastatic-rcc-onclive 2024-09-13T17:54:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-subcutaneous-formulation-of-ocrelizumab-for-relapsing-and-progresive 2024-09-13T17:51:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-subcutaneous-formulation-of-ocrelizumab-for-relapsing-and-progresive 2024-09-13T17:51:54+00:00 weekly 0.7 https://trial.medpath.com/news/cidara-axes-30-of-staff-to-focus-on-flu-prevention-drug-pharmaceutical-technology 2024-09-13T17:46:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cidara-axes-30-of-staff-to-focus-on-flu-prevention-drug-pharmaceutical-technology 2024-09-13T17:46:59+00:00 weekly 0.7 https://trial.medpath.com/news/cipher-pharmaceuticals-partner-moberg-pharma-ab-provides-update-on-mob-015-phase-3-study 2024-09-13T17:38:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cipher-pharmaceuticals-partner-moberg-pharma-ab-provides-update-on-mob-015-phase-3-study 2024-09-13T17:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/novel-adc-azd8205-demonstrates-manageable-safety-profile-and-preliminary-efficacy-in 2024-09-13T17:28:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-adc-azd8205-demonstrates-manageable-safety-profile-and-preliminary-efficacy-in 2024-09-13T17:28:15+00:00 weekly 0.7 https://trial.medpath.com/news/inflammatix-raises-57m-to-advance-test-for-infection-sepsis-medtech-dive 2024-09-13T16:47:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflammatix-raises-57m-to-advance-test-for-infection-sepsis-medtech-dive 2024-09-13T16:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-dupilumab-for-adolescents-with-chronic-rhinosinusitis-with-nasal-polyps 2024-09-13T16:42:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-dupilumab-for-adolescents-with-chronic-rhinosinusitis-with-nasal-polyps 2024-09-13T16:42:28+00:00 weekly 0.7 https://trial.medpath.com/news/engineered-parasite-delivers-therapeutic-proteins-to-the-mouse-brain-nature-biotechnology 2024-09-13T16:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/engineered-parasite-delivers-therapeutic-proteins-to-the-mouse-brain-nature-biotechnology 2024-09-13T16:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/new-guidance-helps-clinicians-use-pemivibart-to-protect-immunocompromised-patients 2024-09-13T16:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-guidance-helps-clinicians-use-pemivibart-to-protect-immunocompromised-patients 2024-09-13T16:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-pembrolizumab-combo-shows-promise-in-thymic-epithelial-tumors 2024-09-13T15:54:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenvatinib-pembrolizumab-combo-shows-promise-in-thymic-epithelial-tumors 2024-09-13T15:54:08+00:00 weekly 0.7 https://trial.medpath.com/news/essential-components-of-an-electronic-patient-reported-symptom-monitoring-and-jama-network 2024-09-13T15:36:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essential-components-of-an-electronic-patient-reported-symptom-monitoring-and-jama-network 2024-09-13T15:36:28+00:00 weekly 0.7 https://trial.medpath.com/news/fixed-duration-vs-continuous-cll-therapy-balancing-efficacy-quality-of-life-and-costs 2024-09-13T15:14:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fixed-duration-vs-continuous-cll-therapy-balancing-efficacy-quality-of-life-and-costs 2024-09-13T15:14:13+00:00 weekly 0.7 https://trial.medpath.com/news/study-identifies-key-factors-for-long-term-weight-loss-with-glp-1-medications 2024-09-13T15:14:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-identifies-key-factors-for-long-term-weight-loss-with-glp-1-medications 2024-09-13T15:14:02+00:00 weekly 0.7 https://trial.medpath.com/news/antisense-oligonucleotide-vo659-reduces-mutant-huntingtin-protein-interim-phase-1-2-data-show 2024-09-13T15:12:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antisense-oligonucleotide-vo659-reduces-mutant-huntingtin-protein-interim-phase-1-2-data-show 2024-09-13T15:12:39+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-or-saxenda-for-weight-loss-which-works-best 2024-09-13T15:09:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-or-saxenda-for-weight-loss-which-works-best 2024-09-13T15:09:49+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-launches-truqap-as-korea-s-1st-akt-inhibitor-for-breast-cancer-patients 2024-09-13T14:53:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-launches-truqap-as-korea-s-1st-akt-inhibitor-for-breast-cancer-patients 2024-09-13T14:53:13+00:00 weekly 0.7 https://trial.medpath.com/news/inhaled-antibiotic-for-bronchiectasis-shows-benefit-and-then-it-doesn-t-medpage-today 2024-09-13T14:41:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inhaled-antibiotic-for-bronchiectasis-shows-benefit-and-then-it-doesn-t-medpage-today 2024-09-13T14:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/endo-presents-data-at-the-american-orthopaedic-foot-ankle-society-annual-meeting 2024-09-13T14:32:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endo-presents-data-at-the-american-orthopaedic-foot-ankle-society-annual-meeting 2024-09-13T14:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/representation-of-women-and-people-of-color-in-clinical-trials-is-crucial 2024-09-13T14:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/representation-of-women-and-people-of-color-in-clinical-trials-is-crucial 2024-09-13T14:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-forecasts-lower-sales-next-year-shares-near-four-year-low-bilyonaryo 2024-09-13T14:27:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-forecasts-lower-sales-next-year-shares-near-four-year-low-bilyonaryo 2024-09-13T14:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/antibody-drug-conjugate-found-effective-against-brain-metastases-in-patients-with-her2 2024-09-13T14:18:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antibody-drug-conjugate-found-effective-against-brain-metastases-in-patients-with-her2 2024-09-13T14:18:33+00:00 weekly 0.7 https://trial.medpath.com/news/enhertu-showed-substantial-clinical-activity-in-patients-with-her2-positive-metastatic-breast 2024-09-13T14:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enhertu-showed-substantial-clinical-activity-in-patients-with-her2-positive-metastatic-breast 2024-09-13T14:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/oshkosh-defense-submits-phase-ii-proposal-for-rcv-program-asdnews 2024-09-13T13:59:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oshkosh-defense-submits-phase-ii-proposal-for-rcv-program-asdnews 2024-09-13T13:59:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-apple-airpods-hearing-aids-tremfya-for-ulcerative-colitis-drug-topics 2024-09-13T13:51:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-roundup-apple-airpods-hearing-aids-tremfya-for-ulcerative-colitis-drug-topics 2024-09-13T13:51:07+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-new-hope-in-the-treatment-of-thymus-gland-cancers-gustave-roussy 2024-09-13T13:32:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-new-hope-in-the-treatment-of-thymus-gland-cancers-gustave-roussy 2024-09-13T13:32:23+00:00 weekly 0.7 https://trial.medpath.com/news/oncology-leaders-highlight-challenges-in-managing-rapidly-evolving-cancer-treatment-data 2024-09-13T13:19:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncology-leaders-highlight-challenges-in-managing-rapidly-evolving-cancer-treatment-data 2024-09-13T13:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/research-extends-hope-for-gastric-cancer-patients-with-peritoneal-metastasis 2024-09-13T13:12:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-extends-hope-for-gastric-cancer-patients-with-peritoneal-metastasis 2024-09-13T13:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/can-glp-1-drugs-help-with-type-1-diabetes 2024-09-13T13:11:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-glp-1-drugs-help-with-type-1-diabetes 2024-09-13T13:11:57+00:00 weekly 0.7 https://trial.medpath.com/news/new-frontiers-in-technology-ai-use-in-clinical-trial-patient-recruitment-in-health-systems 2024-09-13T13:01:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-frontiers-in-technology-ai-use-in-clinical-trial-patient-recruitment-in-health-systems 2024-09-13T13:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-to-present-data-from-multiple-early-stage-clinical-trials-at-esmo-2024 2024-09-13T13:00:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-to-present-data-from-multiple-early-stage-clinical-trials-at-esmo-2024 2024-09-13T13:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-to-present-first-results-from-platinum-resistant-ovarian-cancer-proc-cohort-of 2024-09-13T12:59:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-to-present-first-results-from-platinum-resistant-ovarian-cancer-proc-cohort-of 2024-09-13T12:59:53+00:00 weekly 0.7 https://trial.medpath.com/news/marengo-therapeutics-announces-clinical-study-collaboration-with-gilead-pr-newswire 2024-09-13T12:56:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marengo-therapeutics-announces-clinical-study-collaboration-with-gilead-pr-newswire 2024-09-13T12:56:57+00:00 weekly 0.7 https://trial.medpath.com/news/depression-five-million-americans-may-benefit-from-psychedelic-therapy-newsweek 2024-09-13T12:30:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/depression-five-million-americans-may-benefit-from-psychedelic-therapy-newsweek 2024-09-13T12:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-moderna-s-mrna-solid-tumour-vaccine-shows-early-promise-clinical-trials-arena 2024-09-13T12:27:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-moderna-s-mrna-solid-tumour-vaccine-shows-early-promise-clinical-trials-arena 2024-09-13T12:27:53+00:00 weekly 0.7 https://trial.medpath.com/news/atea-pharmaceuticals-provides-update-on-global-phase-3-sunrise-3-trial-evaluating 2024-09-13T12:26:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atea-pharmaceuticals-provides-update-on-global-phase-3-sunrise-3-trial-evaluating 2024-09-13T12:26:48+00:00 weekly 0.7 https://trial.medpath.com/news/ira-implementation-reshapes-cancer-drug-development-and-patient-access-landscape 2024-09-13T12:11:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ira-implementation-reshapes-cancer-drug-development-and-patient-access-landscape 2024-09-13T12:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-gsk 2024-09-13T12:06:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-gsk 2024-09-13T12:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelic-therapeutics-clinical-trials-research-report-globenewswire 2024-09-13T10:58:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psychedelic-therapeutics-clinical-trials-research-report-globenewswire 2024-09-13T10:58:33+00:00 weekly 0.7 https://trial.medpath.com/news/cooperation-across-healthcare-service-levels-for-medication-reviews-in-older-people-with 2024-09-13T10:50:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cooperation-across-healthcare-service-levels-for-medication-reviews-in-older-people-with 2024-09-13T10:50:24+00:00 weekly 0.7 https://trial.medpath.com/news/nvo-with-obesity-drug-demand-surging-is-novo-nordisk-a-buy-stocknews 2024-09-13T10:47:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nvo-with-obesity-drug-demand-surging-is-novo-nordisk-a-buy-stocknews 2024-09-13T10:47:52+00:00 weekly 0.7 https://trial.medpath.com/news/better-quicker-and-more-effective-treatment-for-patients-with-sepsis 2024-09-13T10:14:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/better-quicker-and-more-effective-treatment-for-patients-with-sepsis 2024-09-13T10:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-mounjaro-help-people-with-type-1-diabetes-control-blood-sugar-lose-weight 2024-09-13T10:09:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-mounjaro-help-people-with-type-1-diabetes-control-blood-sugar-lose-weight 2024-09-13T10:09:25+00:00 weekly 0.7 https://trial.medpath.com/news/trial-of-67cu-sar-bispsma-in-mcrpc-progresses-through-multi-dose-cohort 2024-09-13T10:04:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-of-67cu-sar-bispsma-in-mcrpc-progresses-through-multi-dose-cohort 2024-09-13T10:04:53+00:00 weekly 0.7 https://trial.medpath.com/news/who-prequalifies-the-first-vaccine-against-mpox 2024-09-13T09:05:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-prequalifies-the-first-vaccine-against-mpox 2024-09-13T09:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-injectable-version-of-roche-s-multiple-sclerosis-therapy-wtvb-1590-am 2024-09-13T09:02:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-injectable-version-of-roche-s-multiple-sclerosis-therapy-wtvb-1590-am 2024-09-13T09:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacovigilance-study-of-the-association-between-peripheral-neuropathy-and-antibody-nature 2024-09-13T08:57:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacovigilance-study-of-the-association-between-peripheral-neuropathy-and-antibody-nature 2024-09-13T08:57:14+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-clinical-trials-conference-to-address-key-industry-challenges-and-innovation-in-copenhagen 2024-09-13T08:50:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nordic-clinical-trials-conference-to-address-key-industry-challenges-and-innovation-in-copenhagen 2024-09-13T08:50:44+00:00 weekly 0.7 https://trial.medpath.com/news/sjpedpanel-a-pan-cancer-gene-panel-for-childhood-malignancies-to-enhance-aacr-journals 2024-09-13T08:20:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sjpedpanel-a-pan-cancer-gene-panel-for-childhood-malignancies-to-enhance-aacr-journals 2024-09-13T08:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to 2024-09-13T08:04:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to 2024-09-13T08:04:59+00:00 weekly 0.7 https://trial.medpath.com/news/nxera-s-partner-cancer-research-uk-to-present-on-phase-1-2a-clinical-trial-with-biospace 2024-09-13T07:54:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nxera-s-partner-cancer-research-uk-to-present-on-phase-1-2a-clinical-trial-with-biospace 2024-09-13T07:54:41+00:00 weekly 0.7 https://trial.medpath.com/news/stapokibart-was-granted-marketing-approval-from-national-medical-products-biospace 2024-09-13T07:42:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stapokibart-was-granted-marketing-approval-from-national-medical-products-biospace 2024-09-13T07:42:25+00:00 weekly 0.7 https://trial.medpath.com/news/nkgen-biotech-s-positive-phase-1-clinical-data-in-moderate-alzheimer-s-disease-advances 2024-09-13T07:42:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nkgen-biotech-s-positive-phase-1-clinical-data-in-moderate-alzheimer-s-disease-advances 2024-09-13T07:42:15+00:00 weekly 0.7 https://trial.medpath.com/news/moberg-pharma-ab-receives-information-about-clinical-cure-in-a-subset-of-patients-in-the 2024-09-13T07:06:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moberg-pharma-ab-receives-information-about-clinical-cure-in-a-subset-of-patients-in-the 2024-09-13T07:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/world-sepsis-day-highlights-critical-need-for-better-trial-design-and-targeted-therapeutics 2024-09-13T06:59:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-sepsis-day-highlights-critical-need-for-better-trial-design-and-targeted-therapeutics 2024-09-13T06:59:58+00:00 weekly 0.7 https://trial.medpath.com/news/international-research-team-proposes-multimodal-treatment-strategy-for-long-covid-and-post-acute-infectious-syndromes 2024-09-13T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/international-research-team-proposes-multimodal-treatment-strategy-for-long-covid-and-post-acute-infectious-syndromes 2024-09-13T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/two-more-new-drugs-approved-under-1-mechanism 2024-09-13T05:25:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-more-new-drugs-approved-under-1-mechanism 2024-09-13T05:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/increased-antimicrobial-use-precedes-b-cell-cancer-diagnosis-by-up-to-a-decade-danish-study-reveals 2024-09-13T05:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/increased-antimicrobial-use-precedes-b-cell-cancer-diagnosis-by-up-to-a-decade-danish-study-reveals 2024-09-13T05:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/research-seeks-to-leverage-ai-behavioral-data-to-improve-mental-health 2024-09-13T04:53:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-seeks-to-leverage-ai-behavioral-data-to-improve-mental-health 2024-09-13T04:53:21+00:00 weekly 0.7 https://trial.medpath.com/news/less-toxic-more-personalized-treatments-on-the-horizon-in-her2-breast-cancer 2024-09-13T04:14:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/less-toxic-more-personalized-treatments-on-the-horizon-in-her2-breast-cancer 2024-09-13T04:14:49+00:00 weekly 0.7 https://trial.medpath.com/news/investigator-initiated-clinical-studies-to-be-launched-following-confirmation-of-tumor 2024-09-13T03:42:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigator-initiated-clinical-studies-to-be-launched-following-confirmation-of-tumor 2024-09-13T03:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-denies-accelerated-approval-path-for-moderna-merck-s-ai-driven-melanoma-vaccine 2024-09-13T03:11:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-denies-accelerated-approval-path-for-moderna-merck-s-ai-driven-melanoma-vaccine 2024-09-13T03:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-scales-back-rsv-ambitions-cuts-pipeline-programs-amid-market-challenges 2024-09-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-scales-back-rsv-ambitions-cuts-pipeline-programs-amid-market-challenges 2024-09-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/halozyme-announces-fda-approval-of-roche-s-tecentriq-hybrezatm-with-enhanze-r-for 2024-09-13T01:52:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/halozyme-announces-fda-approval-of-roche-s-tecentriq-hybrezatm-with-enhanze-r-for 2024-09-13T01:52:11+00:00 weekly 0.7 https://trial.medpath.com/news/equitable-breakthroughs-in-medicine-development-eqbmed-to-work-with-inaugural 2024-09-13T01:00:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/equitable-breakthroughs-in-medicine-development-eqbmed-to-work-with-inaugural 2024-09-13T01:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lilly-s-ebglyss-lebrikizumab-for-atopic-dermatitis 2024-09-13T00:09:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lilly-s-ebglyss-lebrikizumab-for-atopic-dermatitis 2024-09-13T00:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/telitacicept-shows-promise-as-alternative-treatment-for-iga-nephropathy-in-real-world-study 2024-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telitacicept-shows-promise-as-alternative-treatment-for-iga-nephropathy-in-real-world-study 2024-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-technology-revolutionizes-pharmaceutical-supply-chain-management-to-combat-drug-shortages 2024-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-technology-revolutionizes-pharmaceutical-supply-chain-management-to-combat-drug-shortages 2024-09-13T00:00:00+00:00 weekly 0.7